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ABSTRACT 
MAST CELL – T CELL INTERACTIONS IN INFLAMMATORY CHEMOKINE 
MEDIATED IMMUNE SURVEILLANCE OF INTESTINAL CANCER 
Sobha R. Bodduluri 
July 11, 2013 
Chronic inflammation promotes a variety of cancers but inflammation also plays 
an important role in immune surveillance of cancer. Chemokine decoy receptor, 
D6 scavenges large number of inflammatory chemokines without transducing any 
signals and thus presumably dampens inflammation. Consistent with this notion, 
the D6 deficient mice displayed enhanced inflammation in variety of disease 
models. However, our laboratory observed that absence of D6 caused an 
unexpected decrease in inflammation and reduced tumor burden in the ApcMin/+ 
mouse model of intestinal cancer. Intestinal tumors in D6-/-ApcMin/+ mice showed 
increased mast cell infiltration but their contribution to tumor progression is 
unknown. Therefore, unravelling the cellular and molecular mechanisms of mast 
cell mediated regulation of intestinal tumor development is the central theme of 
this dissertation. 
Studies described in three specific aims utilize a combination of genetic, molecular 
and immunologic approaches to establish the importance of mast cells in the D6-/-
ApcMin/+ model. Chapter III describes generation and characterization of the mast 
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cell deficient D6-/-SA-/-ApcMin/+ mice. The results showed that the absence of mast 
cells led to decreased survival of these mice due to rapid progression of the 
intestinal adenomas.  However, mast cells did not have a significant impact on the 
rate of tumor initiation in this model.  In Chapter IV, we established cultures of bone 
marrow derived mast cells (BMMCs) from WT and D6-/- mice. Analysis of total RNA 
from these cells by microarrays, real-time PCR showed that chemokine receptors, 
CCR2 and CCR5 are highly upregulated in D6-/- BMMCs compared to WT cells. 
The enhanced mRNA expression also correlated well with the enhanced protein 
and function of CCR2 and CCR5 in D6-/- BMMCs. Further studies will be required 
to identify the relevance of CCR2 and CCR5 to enhanced mast cell migration into 
D6-/-ApcMin/+ tumors.  
In Chapter V, immunofluorescence studies on the extent of mast cell and 
CD8+ T-cell infiltration into intestinal adenomas of ApcMin/+, D6-/-ApcMin/+ and D6-/-
SA-/-ApcMin/+ showed that cytotoxic T-cell infiltration is dependent on mast cell 
presence in the tumors. In contrast, analysis of D6-/-Rag2-/-ApcMin/+ tumors showed 
T-cell independent mast cell homing into these tumors. Further studies with 
cultured mast cells and CD8+ T-cells showed that D6-/- mast cells are capable of 
efficient antigen presentation to induce proliferation and activation of the cytotoxic 
potential of T-cells. The data suggests that mast cells act upstream of T-cells in 
mediating effective immune surveillance of intestinal cancers. These results would 
have important implications in designing immunotherapeutic approaches involving 
mast cell mediated anti-tumor immunity. 
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CHAPTER I 
GENERAL OVERVIEW 
 The major focus of this research dissertation is to understand the role of 
inflammatory chemokines in the development and progression of intestinal 
cancers. This chapter begins with a brief overview of the duality of the immune 
system functions during carcinogenesis. Many studies have established strong 
links between chronic inflammation and cancer progression and there are equally 
compelling arguments about the immune system being an efficient fighter against 
cancer. What turns a tumor protective inflammation into a promoting response is 
the major unknown in tumor immunology and an outline of the cellular and 
molecular mechanisms are emerging. The chapter also provides a brief summary 
of the chemokines and their role in leukocyte migration with particular emphasis 
on the chemokine decoy receptor, D6 and the earlier studies from our laboratory 
that identified the protective phenotype of D6-null mice in the ApcMin/+ background. 
Since the cellular and molecular mechanisms of mast cell mediated inflammation 
in cancer is the major focus of this research, the role of mast cells in carcinogenesis 
is discussed in detail towards the end of the chapter.
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BACKGROUND 
Inflammation and cancer 
The connection between chronic inflammation and cancer has been well 
established now from clinical studies and animal models, since the initial 
observation that leucocytes are present in tumor biopsy samples by Virchow in 
1863. The reduction in cancer incidence and mortality by non-steroidal anti-
inflammatory drugs underscores the importance of inflammation in cancer.  About 
10-15% of cancers are hereditary and rest of cancers are caused by somatic 
mutations and environmental factors such as chronic infections, tobacco smoking, 
particle inhalation and dietary factors [1]. Chronic inflammation triggered by 
infections, tobacco smoking and obesity increases the risk of developing gastric, 
colon and pancreatic cancers. Inflammation can also result from activation of 
oncogenes or inactivation of tumor-suppressor genes at genetic level. Tumors are 
initiated in this inflammatory environment from mutations produced by reactive 
oxygen species (ROS) and reactive nitrogen intermediates (RNI) [2]. Dextran 
sodium sulfate (DSS), the reagent used to induce chronic inflammation causes 
colonic adenomas through DNA damage also [1]. The hallmark of inflammation is 
the activation of transcription factors NF-kB, STAT3 and HIF1α in tumors and 
promoting tumor growth. This will lead to the production of inflammatory cytokines, 
chemokines and prostaglandins in tumors, which in turn will attract leukocytes. 
Once tumors are initiated, infiltrating immune cells also activate the same 
transcription factors and produce more inflammatory mediators generating cancer 
related environment (Reviewed in Ref [1, 2]).  
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In the AOM-DSS induced colon cancer model, inactivation of NF-қB in 
epithelial cells resulted in reduced tumor number without effecting tumor size, 
whereas inactivation of NF-қB in myeloid cells reduced tumor size [3].  NF-қB 
promotes tumor initiation in epithelial cells by suppressing apoptosis and in 
myeloid cells activating tumor promoting inflammatory mediators COX-2, MMP-9, 
KC, and MIP-2 production and tumor growth [4]. STAT3 is activated in tumor and 
immune cells and involved in inhibition of apoptosis and tumorigenesis [5]. Hypoxic 
conditions in growing tumors will lead to HIF1α activation and production of 
vascular endothelial growth factor (VEGF). VEGF activates endothelial cell 
migration and also recruitment of the tumor associated macrophages (TAMS), 
which in turn promote angiogenesis [6]. 
Irrespective of the origin of inflammation, the tumor promoting inflammation 
and tumor inhibiting immunity coexists in tumor environment which consists of 
cancer cells, surrounding stroma and immune cells [7]. In this environment, if tumor 
is not rejected the pro tumorigenic conditions persist. Schreiber and colleagues 
have pioneered the concepts of immune surveillance and proposed that cancer 
immunoediting is a process by which the immune system controls tumor outgrowth 
is comprised of three phases: elimination, equilibrium and escape [7-9]. While the 
mechanisms are still being worked out, studies in implantable models as well as 
chemical induced spontaneous cancers revealed that effective immune 
surveillance requires adaptive immune system and cytotoxic T-lymphocytes to 
keep cancer in an occult state for prolonged periods [10]. Recent cancer exome 
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analysis from Schreiber’s group revealed a T-cell dependent mechanism of cancer 
immunoediting [11]. 
Except for tumor inhibiting Natural Killer (NK) cells, most immune cells can 
play both tumor promoting and tumor inhibitory functions. Tumor associated 
macrophages (TAMs) and T cells are most abundant within the tumor. TAMs 
promote tumor growth and their numbers correlates with poor prognosis [12]. The 
increase in CD8+ cytotoxic T cell and Th1 cell numbers correlate with better 
prognosis in colon cancer [13]. In this study, colorectal tumors from patients 
without recurrence had higher CD3+, CD8+, memory T cells supporting the role of 
T cells in immune surveillance.   
Chemokines signaling and decoy receptors  
One of the ways tumor promoting or tumor suppressing inflammation can 
be controlled is by sequestration of chemokines and cytokines involved in 
inflammatory cell recruitment in the vicinity of tumor. Over the last two decades 
about 50 human chemokines have been identified as a family of functionally 
related small secreted molecules with leukocyte chemoattractant and cytokine-like 
activities [14-16]. Chemokines exert their biological activities by interacting with a 
distinct subfamily in the rhodopsin-like seven transmembrane G-Protein coupled 
receptor (GPCR) super family [17, 18].  At this time, 18 chemokine receptors have 
been molecularly defined, 10 for CC chemokines (CCR1 to 10), 6 for CXC 
chemokines (CXCR1 to 6), and 1 for C chemokines and CX3C chemokines (XCR1 
and CX3CR1, respectively) [19, 20]. Figure 1 shows the current classification of 
the known chemokines according to common and official nomenclature [21], their 
 
5 
 
receptors, ligand receptor specificity as well as sites of receptor expression. 
Chemotaxis induced by chemokines plays a crucial role in leukocyte migration, 
both during resting conditions for control of leukocyte homeostasis (constitutive 
chemokines) as well as under conditions of infection and/or inflammation induced 
by proinflammatory mediators (inflammatory chemokines). 
 
 The seven transmembrane chemokine receptor D6 binds specifically to 
inflammatory CC-chemokines without transducing any intracellular signals 
necessary for chemo attraction [22]. The D6 receptor internalizes its pro 
inflammatory ligands through a β-arrestin dependent pathway, targets them to 
degradation and thus clears inflammatory response [22]. The role of D6 in 
scavenging inflammatory chemokines is evident from different animal models 
using D6 null mice. The D6 deficient mice had accumulated higher amount of 
inflammatory chemokines in skin compared to wild type mice after phorbal ester 
application [23]. The human D6 receptor is normally expressed on lymphatic 
endothelial cells within the skin, gut and lung tissues [24]. Later, it was shown by 
quantitative real time polymerase chain reaction (qPCR ) analysis of human and 
murine leukocytes, D6 expression was highest in B cells and DCs and lowest in  
monocytes and T cells [25].  They detected moderate levels of D6 expression in 
mast cells and neutrophils. They also showed using conditional deletion of GATA1, 
that D6 expression is GATA1 dependent. In myeloid cells, proinflammatory LPS 
down regulated the D6 expression and anti-inflammatory TGF-β upregulated D6 
expression. The D6 expression is negatively correlated with lymph node 
metastasis in breast cancer patients and positively correlated with their survival 
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[26]. The D6 null mice developed by the Sergio Lira’s group have been 
instrumental in working out many biological activities mediated by this receptor. 
These mice when tested in many models of inflammatory disease models such as 
chemical-induced cutaneous inflammation [23, 27], ovalbumin or Mycobacterium-
induced lung inflammation [28, 29], lipopolysaccharide (LPS)-induced placental 
inflammation (abortion model) [30] and methylcholanthrene/phorbol ester (TPA)-
induced skin cancers [31] showed exaggerated inflammation reinforcing the 
concept that the natural function of D6 is to limit inflammation by chemokine 
scavenging.  
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Figure 1: Leukocyte expression and ligand specificity of chemokine receptors. 
Candidate decoy receptors and their tissue expression pattern are listed on the left, 
signaling receptors and their tissue expression pattern on the right. The central columns 
list chemokines, identified with one old acronym and with the new nomenclature in which 
the first part of the name identifies the family and L stands for ‘ligand’ followed by a 
progressive number (Adopted from [21]). 
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D6-/-ApcMin/+ mice 
The ApcMin/+ mice contains a truncation mutation at codon 850 of the 
Adenomatous polyposis coli (APC) gene, unable to sequester β-catenin in 
cytoplasm leading to accumulation of β-catenin in nucleus and activation of wnt 
target genes [32, 33]. This results in polyp initiation in the small intestine and colon. 
The ApcMin/+ mice die at around 150 days of age from anemia and cachexia. In 
humans, mutations in the Apc gene lead to exclusively colon cancer, whereas the 
cause of death in ApcMin/+ mice is related to the severe anemia due to the large 
number of small intestinal adenomas. The average D6-/-ApcMin/+ mice survived for 
208 days and showed delayed onset of the disease compared to ApcMin/+ based 
on hematocrit values (Fig. 2A).  In agreement with the hematocrit data (2B), D6-/-
ApcMin/+ mice displayed delayed onset of tumor development in the small intestine 
and showed significantly reduced tumor burden (Fig. 3). Since it was already 
known with ApcMin/+ model, inflammation played a major role in intestinal polyp 
development, the mRNA from D6-/-ApcMin/+ mice tumors were analyzed for pro-
inflammatory markers by qPCR. The CXCL-1, TNF-α, IL-1 β, COX-2 levels 
decreased in D6-/-ApcMin/+ mice compared to ApcMin/+.mice. It was further observed 
that tumors from D6-/-ApcMin/+ mice contained less actively proliferating cells and 
more apoptotic cells compared to ApcMin/+.mice (Fig. 4) We hypothesized the 
decrease in tumor size in D6-/-ApcMin/+ is due to decreased inflammation.  However, 
the puzzle is why the loss of a chemokine scavenging D6 receptor resulted in 
decreased inflammation? This question was addressed using microarray analysis 
comparing the gene expression profiles of D6-/-ApcMin/+ with ApcMin/+ intestinal 
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tumors.  The microarray data showed that tumors from D6-/-ApcMin/+ are highly 
enriched in mast cell proteases 1, 2 relative to ApcMin/+ tumors (Fig. 5). This data 
was confirmed by qPCR analysis as well as histochemical staining (Fig. 6A) and 
Western blot analysis (Fig. 6B). However, whether this increase in mast cells is 
directly related to the reduced tumor burden in D6-/-ApcMin/+ mice is unknown and 
therefore is a major focus of our study.   
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Figure 2: Decreased mortality and anemia in D6-/-ApcMin/+ mice (A) Kaplan-Meier plot 
of survival of D6 deficiency on the life expectancy of ApcMin/+ mice. Survival curves from 
ApcMin/+ (n=27), D6+/-ApcMin/+ (n=20), and D6-/-ApcMin/+ mice (n=30) are shown. Difference 
in survival of ApcMin/+ mice compared to the two other strains was found to be significant 
by the Mantel-Haenszel/Log-rank test (P<0.0001). The mean survival for ApcMin/+ is 154 
days, D6+/-ApcMin/+ is 201 days, and D6-/-ApcMin/+ is 208 days. (B) Severe anemia in 
ApcMin/+ mice compared to D6-/-ApcMin/+ mice Hematocrit values were determined for the 
indicated mice at the age of ~110 days. Statistical analysis was performed using Mann-
Whitney U test. ***=p<0.001; **=p<0.01, *=P<0.05. 
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Figure 3: Decreased tumor burden in D6-/-ApcMin/+ mice. (A) The total number of polyps 
in the small intestine were quantified by stereoscopic microscopy in age-matched (100-
110 days old) ApcMin/+ (n=12) and D6-/-ApcMin/+ (n=11) mice. The frequency (B) and size 
distribution (Pro: Proximal, Mid: Middle, Dis: Distal regions) (C) of polyps in the small 
intestine are shown. Statistical analysis was performed using Mann-Whitney U test. 
***=p<0.001; **=p<0.01, *=P<0.05.  
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Figure 4: Decreased proliferation and increased apoptosis in D6-/-ApcMin/+ mice 
tumors. (A) 5-Bromodeoxyuridin (5-BrdU) was injected into mice 2 hrs before euthanizing. 
The cross sections of distal small intestine were stained with anti-BrdU antibody. 
Immunohistochemical (IHC) analysis of 5-BrdU-incorporation showed a significant 
decrease in the number of proliferating cells in ileum polyps of D6-/-ApcMin/+ mice. BrdU 
positive cells are counted from 20X images of 5-6 tumors from 3 mice per genotype. (B) 
Terminal deoxynucleotidyl Transferase Biotin-dUTP Nick End Labeling (TUNEL) stain 
performed on distal small intestines of ApcMin/+ and D6-/-ApcMin/+ mice. The number of 
TUNEL positive apoptotic cells are significantly increased in D6-/-ApcMin/+ tumors compared 
to ApcMin/+ mice. Statistical analysis was performed using Mann-Whitney U test (**=p<0.01; 
*** = P<0.001). 
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Figure 5:  Increased expression of Mcpt1 and Mcpt2 in D6-/-ApcMin/+ tumors.    
Small intestine (top panels) and colon (bottom panels) tumors; Left panels 
Fold change from microarray analysis Mcpt1 and Mcpt2 are shown. These were 
derived from pair wise comparisons between D6-/-ApcMin/+, ApcMin/+ mice small 
intestinal or colon tumors as indicated with wild type normal small intestine or colon 
tissue levels as baseline. Middle and Right Panels: Validation of microarray data 
by RT-qPCR. Relative fold change of mRNA levels of Mcpt1 (Middle panel) and 
Mcpt2 (left panel) RT-qPCR using SyBR method as described in methods. 
Statistical analysis was performed using unpaired t test (**=p<0.01, *=p<0.05). 
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Figure 6: Increased chymase activity and MCPT1 protein levels in in D6-/-ApcMin/+ 
tumors (A) Increased chymase activity in D6-/-ApcMin/+ tumors. Histochemical staining 
for chymase activity was performed using Leder’s esterase reaction (blue stain) on distal 
intestine paraffin-embedded tumor sections of ApcMin/+ and D6-/-ApcMin/+ mice. The scale 
bar indicates 100 µm. Chymase positive cells from at least 15 small intestinal tumors (3-4 
mice for each genotype) were counted at 40x magnification. (B) Increased Mcpt1 protein 
in D6-/-ApcMin/+ tumors. Western blot of the tissue lysates from normal ileums of WT, D6-
/- and distal small intestinal tumor lysates of ApcMin/+, D6-/-ApcMin/+ was performed with anti-
mouse Mcpt1 antibody. The same blot was stripped and probed for -actin. The 
quantification of band intensities was determined using Quantity One 4.0.3 software (Bio-
rad) and expressed as a ratio of Mcpt1/-actin. 
 
15 
 
Biology of mast cells 
A urochordate contained cells that resembled connective tissue type mast 
cells. Thus, mast cells evolved long before the evolution of an active adaptive 
immune system [34]. Mast cells originate in bone marrow from CD34+ progenitors 
and enter blood circulation in immature state expressing CD117 and mast cell 
proteases. Mast cells complete their differentiation in tissue environment 
expressing IgE receptors. Murine mast cells can be distinguished based on their 
tissue localization and secretory granule contents. The connective tissue type mast 
cells (CTMCs) found in the skin, lung, serosa and muscularis propria of intestine 
express large amounts of heparin and can be distinguished from heparin lacking 
mucosal mast cells (MCs) found in the mucosa of gut and lung by staining with 
bereberin or safranin. They interchange their phenotype depending on tissue 
environment. The stem cell factor (SCF) and its membrane bound receptor CD117 
(C-kit) are responsible for mast cell growth and mutations in either of the proteins 
lead to mast cell deficiency. The mast cell number increases in tissues either by 
new recruitment of mast cell progenitors or proliferation of local mast cells. The 
standard procedure of culturing mast cells from bone marrow precursors in vitro is 
using stem cell factor SCF and IL-3.The mast cell number and phenotype in in vitro 
cultures can be influenced by addition of Th2-associated cytokines IL-4, IL-9 and 
TGF-β1 to the medium [35, 36]. 
 Mast cells are sentinels of the immune system distributed along the skin, 
airways and gastrointestinal tract surfaces where pathogens and allergens are 
encountered continuously. Mast cells in allergic type of a reaction produce 
 
16 
 
histamine, leukotrienes, prostaglandins, and TNF-α upon Antigen-IgE activation 
[37]. They are not only important mediators of allergy, anaphylaxis but also are 
involved in host defense and are capable of responding to pathogens by rapidly 
releasing preformed TNF-α rapidly and mediate T-cell recruitment to local lymph 
nodes  leading to lymph node enlargement  [37]. Mast cells can promote T cell 
migration directly by producing  IL-16, CXCL-1, CCL1-5, IL-16, CCL20, CXCL10 
and LTB4 [38]. Mast cells activated by IgE cross linking, release leukotrienes 
including LTB4. LTB4 attracts BLT1 expressing effector T cells through vascular 
endothelium [39]. LTB4 is essential in host defense, arthritis and asthma. The  
immunomodulatory role of mast cells in no-tumor setting is highlighted in this 
review [40]. Because the focus of the current research further discussion of mast 
cell functions in this chapter are limited to cancer.  
Role of Mast cells in cancer  
Paul Ehrlich, in his 1893 thesis on the application of aniline dyes described 
how to stain specifically certain granular cells and called them Mastzellen [41].  He 
was able to identify mast cells in several tumors using his pioneering histochemical 
techniques instead of normal histological methods common at that time. Mast cells 
are recruited to tumors as a host defense mechanism and play a direct or indirect 
role in reducing the tumor burden. The direct ways of mast cells killing tumor is by 
releasing cytotoxic granules or engulf and destroy them by phagocytosis. The 
indirect ways of effecting tumorigenesis is through release of mediators such as 
heparin, Granzyme B, cathepsin and TNF- or immune surveillance through 
cytotoxic T-cells. 
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Mast cells play a dual role depending on the stromal environment [42]. They 
can promote tumorigenesis through secretion of heparin, IL-8 and VEGF mediating 
vascular growth, growth factors promoting tumor growth and histamine which is 
immunosuppressive. Mast cells also produce cytokines and proteolytic enzymes 
that are damaging to tumor cells. 
 
Pro tumorigenic role of mast cells in human cancer 
Since Ehrlich’s days there is no dispute in acknowledging the presence of 
mast cells in tumors, but significance of their presence, good or bad is divided. It 
is possible whether mast cells play a dual role in tumor progression depends on 
tumor setting. Mast cells release several factors such as TNFα, TGF, FGF-2, 
VEGF, PDGF, IL-8, Osteopontin and NGF that are involved in tumor progression 
and angiogenesis. Mast cell produced cytokines such as IL-1, IL-2 and IFNγ can 
also bring immune response leading to tumor inhibition [42]. 
The type of mast cells in the tumor can also change the outcome of tumor 
growth. When breast lesions were double stained for tryptase and chymase, 
benign tumors have equal number of tryptase and chymase containing cells 
whereas malignant tumors have three times more tryptase positive cells than 
chymase positive cells [43]. The tryptase positive cells are more concentrated at 
the edge and most likely involved in tumor growth. 
 In hepatocellular carcinoma model, peritumoral infiltration of mast cells are 
associated with bad prognosis [44]. In this study, 207 patient surgically removed 
tumor samples were stained with tryptase and the patient survival was followed for 
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five years. They found higher number of mast cells in peritumoral region correlated 
with poor prognosis. Not only mast cells, Foxp3 stained T-regs also increased in 
these tumors suggesting presence of mast cells combined with T-regs indicated 
recurrence of the disease.   
 Bellone et al analyzed mRNA expression and protein levels of SCF and c-
kit in normal, premalignant adenomas and malignant colon tissues from 126 
patients [45]. SCF and c-kit mRNA is expressed in all tissues. C-kit- protein is 
expressed in ~10% of adenomas or adenocarcinomas. SCF is expressed in 25% 
of adenomas but co expressed in 80% of adenocarcinomas. The co expression of 
SCF and c-Kit in malignant tumors indicate there is autocrine loop for SCF 
expression and negative correlation for this axis in CRC [45]. 
In a colon cancer study analysis of 325 stage I and III advanced colon cancer 
patients, Xianrui et al found that high number of tryptase antibody positive cells are 
associated with poor clinical out come in CRC patients affecting overall survival 
and also disease free survival [46]. They also noted mast cell infiltration is more in 
male patients.  Mast cells were found to stimulate tumor growth by producing 
proteases and angiogenesis factors in mouse models of skin [47] and pancreatic 
cancers [48].   
Anti-tumor role of mast cells in human cancers 
In contrast to the few human studies that suggested pro tumor role for mast 
cells large number of studies clearly outline a protective role for mast cells in variety 
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of human cancers including breast, prostate, oral, ovarian, pancreatic, gastric and 
colon cancers.  
 Aaaltoma et al. studied 187 women with breast cancer during 1978-1990 
for mast cell infiltration into tumor stroma and correlated mast cell number with 
histological characters and survival [49]. No significant relationship could be drawn 
with histological features and mast cell density. However, the high mast cell 
numbers in breast tumor is  associated with high survival probability and low mast 
cell number is associated with low survival probability indicating mast cell density 
could be used as prognostic factor [49]. Malignant tumors also have reduced 
histamine content relating with low mast cell number.  The CD117 staining of tissue 
microarrays (TMAs) from 348 invasive breast carcinoma patients in a 20 year 
follow up study also showed mast cell presence in peritumoral stroma is beneficial 
and serves as a good independent prognostic indicator [50]. They also studied 
hormonal status and estrogen and progesterone are positively correlated whereas 
Her2 is negatively correlated with survival. Macrophage number is negatively 
correlated with survival and no correlation was seen with B-cells and T-cells. They 
suggested IL-4 secretion by mast cells can cause apoptosis of cancer cells [50]. 
  Tryptase staining of invasive breast cancer  Patient TMAs showed high 
mast cell number is associated with low tumor grade, even though there is no 
statistically significant correlation with overall survival [51]. Three other studies in 
oral squamous cell carcinomas [52] and in B cell Lymphomas  [53] and ovarian 
cancer [54] pointed out that patients with higher mast cell density in tumors had  
significant survival advantage.  
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 In a recent study, a large cohort (2300) of prostate cancer patients surgically 
removed tissue samples were stained for CD117 tissue microarray format and 
followed their survival for 10 years. Higher intra tumoral mast cell density clearly 
correlated with better survival in prostate cancer [55]. Johansson group in their 
study of large pancreatic cancer patients also confirmed the good prognostic value 
of intra tumoral mast cells [55]. In their study, they showed how mast cells can 
have different effect in tumor progression depends on their location in the same 
cancer setting. They noticed mast cells in peritumoral area correlated with poor 
survival. They used orthotopic rat model and showed peritumoral mast cell cells 
stimulated tumor growth [56].  They suggested that peritumoral mast cells promote 
angiogenesis and tumor growth by secreting growth factors like FGF-2. 
 Mast cell densities in gastric tumor biopsies were determined with toluidine 
blue staining [57]. Benign tumors are three times more than malignant tumors in 
210 samples. Mast cell density is higher in benign tumors than malignant tumors 
and within malignant tumors mast cells are present only in well differentiated 
tumors not in poorly differentiated tumors. They postulated mast cell are 
accumulated in tumors as a host defense mechanism and also have a role in 
angiogenesis leading to for malignant cell growth. Lack of mast cells in poorly 
differentiated tumors could be that they are self-sufficient and do not need mast 
cell factors as demonstrated in prostate tumors 
 Nielsen et el showed high mast cell number correlated with better patient 
survival  using  intra-operative tumor  tissue samples from 584 colorectal cancer 
(CRC) patients and followed their survival for five years [58].  They stained not only 
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for lymphocyte infiltration into tumors, but also for other inflammatory immune cell 
distribution.  Both high counts of lymphocytes and individual high counts of mast 
cells, eosinophils and neutrophils in tumors correlated with better survival. 
However, prognostic role of mast cells in CRC was defined using small cohort 
studies in many of previous studies [59].  Further research efforts are needed to 
define the role of the mast cells in human CRC progression with larger cohorts.  
The pathways are often different between tumor initiation and tumor 
progression [59]. In ApcMin tumorigenesis polyp initiation and progression are not 
effected at same time as the other. Thus, mast cells also may effect either initiation 
or size of colorectal tumors. TGF-β is known for both pro or anti-tumor 
development depends on the tumor setting. TGF at basal level prevents tumor 
development and latter promotes tumor development [60]. 
 In a different study, colon cancer patients were followed for five years [61] 
and tumor samples were carefully chosen for the analysis unlike earlier studies 
where they combined colon and rectal tumors and also did not differentiate 
between different TNM stages. This group used only stage III B tumor tissues and 
stained for mast cell tryptase. They found normal mucosa surrounding the tumor 
tissue was enriched with more mast cells than the tumor core, but there is no 
correlation of primary tumor mast cell number with survival. Mast cell number in 
lymph node metastasis and draining lymph node are also not correlated with 5 
year survival. This study clearly shows mast cells are not involved in tumor 
promotion.  
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Role of mast cells in mouse tumor models 
Role of mast cells in mouse models colon cancer has been studied by few 
groups. Tanaka and Ishikawa [62] looked at mast cell role in AOM/DSS induced 
colon cancer model using control WBB6F1 and mast cell deficient WBB6F1- kit 
w/W-v mice. After 20 weeks, the tumor multiplicity of adenoma and adenocarcinomas 
were significantly higher in control mice than mast cell deficient mice but there is 
no statistically difference in tumor incidence. They looked at the inflammatory 
chemokines profile in colons at 12 weeks and found several of them significantly 
lower in mast cell deficient mice.   
 Mast cells both connective and mucosal type are recruited into intestinal 
polyps in two murine models of polyposis, -catenin overexpressed mice and 
APC468 mice with truncated APC gene [63]. The polyp number was reduced after 
bone marrow devoid of mast cell progenitors was transferred suggesting mast cell 
role in tumor development.  The anti-tumor role of mast cells also well 
demonstrated by crossing ApcMin/+ with mast cell deficient SASH mice [64]. The 
genetic ablation of mast cells in ApcMin/+ increased the tumor number and size 
indicating the mast cells are protective in tumorigenesis. Tumor cell proliferation is 
not different in mast cell deficient SASHMin/+ compared to ApcMin/+ mice.  The 
apoptosis is significantly reduced in SASHMin/+ mice tumors explaining increase in 
size of the tumors. They did not see any difference in T cell, neutrophil recruitment 
but eosinophils are significantly reduced in SASHMin/+ compared to ApcMin/+. They 
suggested that direct cytotoxic effect of mast cell granules to tumors or eosinophil 
mediated increase in apoptosis as possible mechanisms in tumor inhibition. The 
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results presented in this dissertation agrees well with the latter study on the tumor 
protective role of mast cells but suggest a clear link to adaptive immunity via T-cell 
activation mediated pathways.  
Mast cell recruitment into tumors  
The mechanisms are not known how mast cells are recruited specifically to 
the periphery or into the tumor core. Chemoattractants recruit mast cells to the 
tumor environment. Rat mast cells migrated to the injection site when MCP-1 and 
RANTES (CCL5) were injected intradermally [65]. In addition to mast cells, 
monocytes and eosinophils also migrated in this model. MCP-1 (CCL2) is a 
chemoattractant to monocytes and basophils.  CCL5 is a chemoattractant for 
monocytes, memory T lymphocytes, CD4+ T-cells. Nine chemokine receptors and 
27 chemokines are expressed by human intestinal mast cells [66]. Chemokine 
expression is upregulated by antigen stimulation but chemokine receptor 
expression is independent. Chemokine receptors on mouse mast cells are 
upregulated by activation of C-kit or FcϵR1. 
 SCF and c-Kit plays crucial role in mast cell recruitment to tumors and also 
restructuring tumor environment. Mast cell migration to tumors was studied in a 
subcutaneous model using variety of different cancer cell lines [67]. In this study 
they detected SCF RNA and protein expression in several tumor cell lines as well 
as corresponding human tumor tissues. Blocking SCF with antibodies inhibited 
mast cell recruitment to tumors. Low concentration of SCF recruits mast cells to 
tumors and higher SCF concentrations activates mast cells. SCF-c-Kit signaling 
facilitates MMP-9 production from mast cells, which will help tumor cells to release 
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more soluble SCF. Higher concentrations of SCF  activated mast cells to up 
regulate several proinflammatory cytokines and chemokines (IL-6, TNF-α, VEGF, 
Cox-2, CCL2) and immune suppressive genes (adenosine, IL-10, Foxp3 and  SCF, 
TGF-β) leading to increase in T-reg population and suppression of T-cells and NK 
cells. Mast cells are capable secreting various mediators without degranulating 
[68]. This was called piecemeal degranulation. Such type of activation of mast cells 
might be a central of immune regulation by mast cells without tissue damaging 
cytotoxicity associated with complete degranulation.  
 In transgenic adenocarcinoma of the mouse prostate cancer (TRAMP) 
model, two different kinds of tumors develop the well differentiated and poorly 
differentiated. Mast cells are recruited to the well differentiated tumors because of 
their high SCF content but not to poorly differentiated tumors [69].  The cell lines 
developed from these tumors were injected back into the wild type mice. The 
tumors developed from well differentiated lines recruited mast cells but not the 
tumors developed from poorly differentiated cell lines. When these cell lines were 
injected into mast cell deficient mice, well differentiated cell lines of epithelial origin 
did not grow and poorly differentiated cell lines of mesenchymal origin grew. The 
well differentiated cell lines are dependent on mast cell generated MMP9 for their 
growth and poorly differentiated cell lines produce MMP9 on their own and are not 
mast cell dependent. It was concluded from these experiments early growth of 
prostate tumors require mast cells to produce MMP9 to invade nearby tissues and 
the more advanced tumors after EMT transition produce their own MMP9 without  
requiring mast cell help [69]. 
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 Mast cells are recruited to the tumor site when Myc is induced with 
tamoxifen in pancreatic -islets. When mast cells are depleted in this model, either 
by stabilizing with cromolyn or by crossing with SASH mice, tumors did not grow 
and apoptosis was increased [48]. Mast cells were responsible for tumor growth in 
this model. Myc activation rapidly induced several chemokines into tumors 
including mast cell chemoattractants CCL2 and CCL5 as demonstrated by 
microarray analysis. These tumors also stained for CCL2 and CCL5 protein 
expression suggesting that they are involved in the early recruitment of mast cells 
to tumors.  
 The activated mast cells in subcutaneous model release multiple 
proinflammatory factors IL-6, TNF-alpha, Cox-2, iNOS, VEGF, IL-17and CCL2, 
responsible for immune suppression and promote tumor growth. Most cancer cells 
do not express c-kit on their membrane [70] and could obtain c-kit from mast cell 
derived exosomes in membrane exchange. The activated mast cells produce 
proteases and proangiogenic factors VEGF, PDGF, MMP9 and tryptases 
promoting metastasis. Thus, mast cells promote tumor growth by increasing 
angiogenesis, remodeling tumor microenvironment and by recruiting suppressive 
immune cells [70]. 
Possible mechanisms for anti-tumor role of mast cells  
Mast cell direct role as anti-tumor effector cells was recognized long time 
back. Peritoneal mast cells were isolated and purified from chemically induced 
fibrosarcoma bearing mice or normal mice and  tested in vitro cytotoxicity assays 
for tumor killing capability [71]. Mast cells isolated from normal or tumor bearing 
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mice were equally cytotoxic to mouse or rat fibrosarcomas and less effective to 
mouse fibroblasts suggesting tumor specific cytotoxicity. Mast cells are capable of 
removing aggressive cancer cells also by phagocytosis  as demonstrated in this 
study of invasive ductal breast carcinomas [72]. Hormone sensitive tumors 
contained more mast cells than hyporesponsive tumors indicating mast cell 
presence is associated with good prognosis. After careful microscopic examination 
of these tumors they identified mast cells phagocytosing cancer cells. They 
showed one or two mast cells engulfing cancer cells with their pseudopodia and 
disintegrating slowly inside the mast cell from their toxic granules.  
 When human mast cell line HMC-1 and human squamous carcinoma cell 
line SCC-25 were co-cultured in vitro, mast cells inhibited SCC-25 cell proliferation. 
Microarray analysis was performed to compare mast cell co-cultured SCC-25 gene 
expression  with control SCC-25 gene expression, one of the up regulated gene is 
apoptosis inducing TRAIL [73] . The mechanism behind mast cells inhibition of 
tumor growth is by reducing proliferation and increase in apoptosis. 
 Immunostaining of various human breast, head and neck, ovarian, lung, non 
Hodgkins and Hodgkins tumors for mast cell tryptase, demonstrated mast cells 
were recruited mainly to peritumoral fibrous tissue. Addition of heparin reduced the 
size and number of breast cancer cell colonies, when grown in the presence of 
fibroblasts but had no effect in the absence of fibroblasts. The mast cell produced 
heparin role in inhibiting the  growth of primary and metastatic tumors was 
suggested based on the peritumoral location of mast cells and in vitro co culture 
of tumor cells with fibroblasts [74].   
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 The drug Imatinub, a specific bcr–abl tyrosine kinase inhibitor used in the 
treatment of multiple cancers is also known to inhibit c-kit on mast cell surface 
effectively and reduce the mast cell numbers and function. Imatinub treatment 
accelerated mammary adenocarcinoma tumor growth in subcutaneous model and 
resulted in peritumoral blood clotting [75]. Inhibition of mast cell specific heparin by 
injecting heparinase into tumors also increased tumor growth in this model. Blood 
clotting promotes tumor growth. Mast cells are recruited to tumors at the periphery 
and their heparin mediated anti-clotting property prevents tumor growth. 
Mast cell regulation of adaptive immunity 
Mast cells can recruit T-cells directly by secreting chemotactic molecules 
such as IL-6, XCL-1(lymphotactin), CCL1-5, IL-16, CCL20,CXCL10 and LTB4 [38]. 
Mast cells activated by IgE cross linking, release leukotrienes including LTB4. LTB4 
attracts BLT1 expressing effector T cells through vascular endothelium [39]. Mast 
cells can also recruit T-cells indirectly by inducing adhesion molecules expression 
on endothelial cells. Mast cell’s  physical interaction with different innate and 
adaptive immune cells and outcome of that interaction is adeptly summarized in a 
recent review by Gri et al. [76]. Mast cell interactions are bidirectional and they are 
capable of delivering and receiving co-stimulatory signals from immune cells 
promoting tumor escape or tumor surveillance. Mast cells interaction especially 
with cytotoxic T-cells are known for long time in mastocytoma cell line p815 studies 
[77]. Mast cells express major histocompatibility MHC-I and MHC-II molecules and 
are able to present antigens to CD8+ and CD4+ T cells, respectively. Mast cells 
can phagocytose bacteria and present OVA containing bacterial antigens to CD8+-
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OVA T-cell hybridomas through MHC-I as efficiently as peritoneal macrophages 
[78]. Selekato et al. showed mast cells induced CD8+ T cells activation, 
proliferation and also CD8+ T-cell cytotoxicity in antigen specific way [79]. They 
demonstrated that adoptively transferred antigen pulsed mast cells are capable of 
activating antigen specific CD8+ T-cell proliferation in an EAE model. Mast cells 
are also capable of suppressing T-regs [80] by IL-6 production through 
OX40/OX40L axis and switching them into IL-17 producing effector cells. The close 
proximity of human tansillar mast cells and T-cells is known in allergy. Tansillar 
mast cells increased T-cell proliferation through OX40/OX40L interaction when co-
cultured in vitro [81]. T-reg cells also inhibit mast cell Fcϵr1 mediated degranulation 
involving OX40/OX40L axis in vitro and in vivo [82].  
Thus, mast cells have wide ranging activities and biological functions. The 
experiments described in this dissertation are aimed at developing a better 
understanding of the mechanisms of their tumor protective functions. 
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CHAPTER II 
Materials and Methods 
Mice 
  D6-/-ApcMin/+ strain was generated in the laboratory by crossing C57BL/6-
ApcMin/+mice (Jackson Laboratory) and D6-/- mice (Schering-Plough). Animals were 
housed in barrier facility under specific pathogen free conditions. The ovalbumin 
specific TCR OT-1 mice, KitW-sh/W-sh mice on the C57BL/6 background (SASH mice 
or SA-/-) were purchased from The Jackson Laboratory. Rag2-/-  mice were 
purchased from Taconic Farms Inc. D6-/-Rag2-/-ApcMin/+ mouse was generated by 
breeding D6-/-ApcMin/+ with Rag2-/- mice. All the experiments were conducted 
according to the protocols approved by the Institutional Animal Care and Use 
Committee (IACUC) at University of Louisville. 
Genotyping  
Genomic DNA from mouse tail (0.1 mm) was extracted from using a Direct PCR 
lysis reagent (Viagen Biotech) according to the manufacturer’s instructions. The 
following primers were used for genotyping of indicated strains.  
1. ApcMin/+ 
WT:    5’ GCCATCCCTTCACGTTAG 3’ 
          ApcMin/+ (KO):  5’ GCCATCCCTTCACGTTAG 3’ 
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Common:  5’ GCCATCCCTTCACGTTAG 3’ 
The expected PCR product size for ApcMin/+ mouse: WT 600 bp; ApcMin/+: 340 bp. 
 
 
2. D6-/- 
WT:    5’ CAGAGCTGAGATGGTCCCAA 3’ 
D6-/-  (KO):   5’ AGCCGTCACCTTAATATGCG 3’ 
Common:  5’ AGTAAGGCTCTCGGTGAACAG 3’ 
 
The expected PCR product sizes for D6-/- mouse: WT 260 bp; KO: 550 bp. 
 
The PCR was performed using Mango Taq polymerase (Bioline) in 30 µl 
reaction containing final concentrations of 1X Mango Taq buffer, 1.5 mM MgCl2, 
0.25 mM dNTPs with 0.5 U of enzyme. The primer concentrations for ApcMin/+ and 
D6-/- was 0.6 μM. The D6-/- genotyping PCR was performed in Effendorf 
Thermocylcer. The PCR conditions: Initial denaturing at 95 C for 2 min, followed 
by 30 cycles of 95 C x 30 seconds, 60 C x 1 min, and 72 C for 1 min. The 
reaction was terminated after 5 min extension at 72 C. Similar conditions were 
used for ApcMin/+  genotyping except for annealing temperature, which was 
performed at 56 C for 1 min. The PCR products were analyzed on 2% agarose 
gel.  The SASH mice (SA-/-) are white due to reduced melanocytes and 
heterozygous mice have black and white color band as name indicates and 
identified easily by coat color without genotyping. 
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Breeding scheme to generate D6-/-SA-/-ApcMin/+  
D6-/-ApcMin/+ strain is maintained by breeding D6-/-ApcMin/+ males with D6-/- 
females and genotyping for ApcMin/+. To generate D6-/-SA-/-ApcMin/+ triple knockout,  
D6-/-ApcMin/+ males were bred with female SA-/- mice and generated heterozygous 
D6+/-SA+/- mice with or without ApcMin/+ allele. The heterozygous D6+/-SA+/-ApcMin/+ 
male mice were then crossed with D6+/-SA+/- and SA-/-  females for several rounds 
to obtain D6-/- SA-/- ApcMin/+ and SA-/- ApcMin/+  male breeders. 
Blood collection for hematocrits and serum 
Mice were euthanized at the age of 110 days by CO2 inhalation, cut open 
and blood was drawn from heart using a 1 ml syringe with 23 gauge needle. 
Approximately 200 µl of blood was taken into EDTA (heparin) coated tubes 
(Sarstedt), mixed gently up and down and stored at 4 C. The blood samples were 
analyzed at room temperature using the Hemavet-950 Hematology System (Drew 
Scientific). For serum, blood was collected into Microtainer (BD Microtnr Sst 
W/gard) allowed to clot for 30 minutes. The blood samples were centrifuged at 
10,000 RCF for 2 minutes and top layer (supernatant) was carefully collected and 
stored at -800C. 
Survival of mice  
Mice (ApcMin/+, SA-/-ApcMin/+, D6-/-SA-/-ApcMin/+) were passively followed for 
long-term survival as per IACUC regulations. The mice were sacrificed, if they were 
found morbid and sick.  Significance of differences in survival was determined by 
the Mantel-Haenszel/ Log-rank test.  
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Enumeration of Polyps  
The intestinal polyps (tumor burden) were analyzed at 110 days of age. The 
mice were euthanized by CO2 inhalation. The visceral layer was opened and the 
pubic bone clipped. The large intestine was removed from the rectal end without 
excess pressure. The rest of the intestine slowly removed without fat and other 
attachments and clipped at the pyloric-duodenum junction. The large intestine or 
colon was cut at illeocecal junction. The remaining small intestine was divided into 
three equal parts i.e., distal, middle and proximal portions. The intestines were 
flushed with 1X PBS using 10 ml syringe and 18 gauge gavage needle to remove 
any fecal samples. Small intestines and colons were longitudinally opened and 
spread on the filter paper and placed another filter paper on top (sandwiched). 
These tissues were fixed in the 10% formalin for 16 hrs followed by transferring 
into 70% alcohol. Tissues are stored in 70% alcohol until counting. The tumors 
were counted and sized under stereo microscope containing reticle eye piece.  
Polyps were categorized as <1mm, 1-2mm, 2-3mm and >3mm size. For each 
experimental group, the incidence of tumors, defined as the number of mice with 
tumors/number of mice in the group. The mean number of tumors/mouse ±SEM, 
and the mean tumor diameter (mm) in the group ±SEM were calculated for the 
small intestine and colon separately. Statistical analysis was performed using the 
Mann-Whitney U test using Graph Pad Prism 4.0 software. 
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Frozen samples for immunohistochemistry (IHC) analysis  
The flushed intestines were filled with OCT and prepared swiss-roll in OCT 
blocks using standard methods. The OCT blocks were used to prepare frozen 
section slides with Cryostat (Leica CM1900).  
Fixing tissues for immunohisotchemistry (IHC) analysis  
The flushed intestines were fixed with 10% neutral formalin buffer for 16 h 
followed by transfer into 70% alcohol. The fixed tissues were prepared as Swiss 
rolls and embedded into paraffin. The sections were cut at 5 m thickness and one 
of the sections used for hematoxylin and eosion (H&E) and others for 
immunohistochemical analysis. 
Bone Marrow-Derived Mast Cell (BMMC) culture  
Bone marrow derived mast cell cultures were prepared from female mice (4 
to 6 weeks old). The mice were euthanized using CO2 inhalation and the rest of 
the procedure was carried out in laminar hood. Tibia and femur bones were 
dissected from these mice. The bone marrow was flushed with RPMI from tibia 
and femur bones gently mushed (pulped) with back of syringe barrel. The cells 
were separated by filtering through 60 µm nylon mesh. The filtrate was centrifuged 
at 450 g for 5 min and the pellet was resuspended in BMMC culture medium 
(DMEM containing 10% FCS,100 units/ml Penicillin, Streptomycin 100 µg/ml, 2 
mM L-Glutamine, 50 µM β-mercaptoethanol) supplemented with 12.5 ng/ml 
recombinant Mouse SCF (R&D # 455 MC,10 μg/ml Stock,) and 10 ng /ml 
recombinant Mouse IL-3 (R&D #403-ML,10 μg/ml Stock). The BMMCs were plated 
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at ~1 X 106 /ml density in T-75 cm2 flask containing 15 ml of medium. The non-
adherent cells were transferred after 48 hours into fresh flasks without disturbing 
the adherent (fibroblast) cells. The flasks were changed weekly or as needed to 
separate the non-adherent mast cells from the contaminating adherent cells. The 
medium was changed once a week with medium containing SCF, IL-3. The 
homogenous population of mast cells were visible after 4 weeks of culture and  
propagated further by dividing once or twice a week to 0.5 -1x10 6 cells/ml density. 
The purity of BMMCs confirmed by surface staining with mast cell specific markers 
c-Kit and FcR1 by FACS analysis. 
Chemotaxis  
Chemotaxis of BMMCs (WT and D6-/-) was evaluated using 5-m pore size 
Transwell filters (Corning Costar, Cambridge, MA). Briefly, cells were resuspended 
at a density of 0.5 x 107/ml in chemotaxis buffer (RPMI-1640, 0.5% BSA). The 
lower chamber was loaded with various concentrations of chemokines in a volume 
of 600 l and 100 l (0.5 x106 cells) of cells from above cell suspension was placed 
onto the upper chamber. After 3 h of incubation at 37 C in 5% CO2, the upper 
chamber was removed and cells in the lower chamber were fixed in buffered 2% 
formaldehyde. The cells migrated were counted by running for fixed time (fixed 
volume of cells) and analyzed using buffer as background control. 
Calcium flux  
Ligand induced calcium mobilization was monitored in INDO-1 loaded cells 
stimulated with various concentrations of chemokines as previously described by 
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Jala et al [83, 84].  Briefly, BMMCs were resuspended in 1X Ca2+, Mg2+ free HBBS 
buffer+1% BSA and loaded with 1 µM Indo-1 in the presence of 1µM pluronic acid 
and placed in tissue culture chamber at 37 C, 5% CO2. After 30 min incubation, 
cells were washed with 1X HBBS, 0.1% BSA and resuspended in the same buffer 
containing 1 mM calcium buffer at 4x106 cells per 2 ml density. All the calcium 
measurements were performed in temperature controlled cuvette chamber with 
constant gentle stirring. The required concentration of ligand (in 20 µl volume) was 
added in to the cuvette containing 2 ml of cells (4x106 cells) at 37 C and the 
emission fluorescence (405 nM and 490 nM) were continuously recorded by 
exciting at 335 nM using F-2500 FL Spectro flurometer (Hitachi). The ratio of 
emission fluorescence represents relative intracellular calcium release/response 
upon stimulation. 
Western blot analysis of MCPT1  
The intestinal tumors were dissected and snap frozen in liquid nitrogen and 
stored at -80C. Freshly dissected or thawed tumors/normal tissues were 
homogenized in Bio-Rad lysis buffer using hand held homogenizer (Omni 
International).  The total proteins from these extracts were quantified using 
Bradford protein estimation method. The extracts (50 µg of total protein) were 
separated on SDS-PAGE and transferred onto PVDF (Biorad) membrane. The 
membrane blot was probed with Rat anti mouse MCPT-1 antibody (R&D) 1 µg/ml 
and peroxidase coupled secondary anti rat antibody. The same blot was stripped 
with stripping buffer (Thermo Scientific) and re-probed for -actin-HRP antibody 
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(Santa-Cruz Biotechnologies).  The blot was developed using Western Blotting 
Luminol Reagent (Santa-Cruz Biotechnologies). 
Real Time PCR 
 RNA was prepared from small intestine and colon tissues of WT, D6-/- as 
well as size matched intestinal tumors of ApcMin/+, D6-/-ApcMin/+, SA-/-ApcMin/+ and 
SA-/-D6-/-ApcMin/+ mice (105-110 days age old) using Trizol and followed by RNeasy 
mini kit from Qiagen. Briefly, tissues were homogenized in Trizol reagent using 
hand held homogenizer with disposable RNAase free homogenizing probes from 
Omni International Inc. Chloroform (1/5 volume of Trizol) was added to 
homogenized sample. These samples were centrifuged at 12000 g for 15 min and 
supernatant was collected. Equal volume of 100% alcohol was added and 
transferred everything onto RNeasy mini column and followed the manufacture’s 
protocols. The RNA was treated with DNAase using Turbo DNAse kit, Ambion Inc 
or on column DNAse treatment (Qiagen DNAse kit) to remove traces of genomic 
DNA contamination. Total RNA from BMMCs, Macrophages, T-cells, B-cells and 
dendritic cells was isolated by lysing samples with Trizol followed by RNeasy mini 
purification kit according to manufacturer’s protocols. The amount of RNA was 
estimated using Nanodrop. 
For semi quantitative real-time PCR, 1 µg of total RNA was reverse 
transcribed in 50 µl reaction using TaqMan reverse transcription reagents (Applied 
Biosystems) using random hexamer primers. 2 µl of cDNA and 1 µM real time PCR 
primers were used in a final 20 µl qPCR reaction with ‘power SYBR-green master 
mix’ (Applied Biosystems). The PCR conditions as follows: Initially, 1 cycle of 50 
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C for 2 min followed by 95 C for 10 min.   Next, 60 cycles of 95 C for 10 sec 
followed by 58 C for 45 sec. The SYBR fluorescence (amplification) was recorded 
at 58 C. The real time primers were purchased from Real Time Primers, LLC, 
Elkins Park, PA. Real time qPCR was performed either in ABI-Prism 7900 
sequence detect system (Applied Biosytems) or Biorad CFX96 real time PCR 
machine. Expression of the target genes was normalized to β-actin and the relative 
fold changes were calculated using the delta CT method by Livak et al. [85]. The 
fold changes are displayed relative to the wild type samples. Data are 
representative of tumors/tissues isolated from at least 5 different mice for each 
genotype. 
Microarray  
Total RNA from WT and D6-/- BMMCs (2week old, 10 weeks old cultures) 
was isolated using Trizol and followed by RNeasy mini kit from Qiagen as 
described above. The micro array was performed using Affymetrix GeneChip® 
Mouse Gene 1.0 ST Array according to manufacturer’s protocol at Microarray core 
facility, University of Louisville. The GeneChip-brand array comprised of over 
750,000 unique 25-mer oligonucleotide features constituting over 28,000 gene 
level probes with an average of 27 probes per gene. Briefly, Total RNA was 
amplified and labeled following the Affymetrix (Santa Clara, CA) standard protocol 
for whole transcript expression analysis, followed by hybridization to Affymetrix 
Mouse Gene 1.0 ST® arrays. The arrays were processed following the 
manufacturer recommended wash and stain protocol on an Affymetrix FS-450 
fluidics station and scanned on an Affymetrix GeneChip® 7G scanner using 
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Command Console 3.1 . The resulting .cel files were imported into Partek 
Genomics Suite 6.6 and transcripts were normalized on a gene level using RMA 
as normalization and background correction method. Contrasts in a 1-way ANOVA 
were set up to compare the treatments of interest. The fold changes along with 
Affymetrix IDs, p-values were uploaded Ingenuity pathway analysis (IPA) software. 
The fold change level (D6-/- vs WT) in chemokines and their receptors were 
represented in graphs. 
Purification of CD8+ T Cells 
CD8+ T cells were isolated from spleen and mesenteric lymph nodes from 
OT-1 mice using standard protocols. Briefly, spleen or lymph nodes were crushed 
and passed through 70 µm strainer (Corning). The red blood cells were lysed with 
RBC lysis buffer (Biolegend). After lysis step, cells were resuspended in 1 ml of 1 
X PBS containing 0.5% BSA and 100 µl of CD8+ a (Ly-2) micro beads (Miltenyi 
Biotec) and incubated for 45 min. The CD8+ cells were purified on MACS LS 
columns. The purified CD8+ T cells were > 95% positive for CD8 as analyzed by 
Flow Cytometer.  
CFSE labeling: The CFSE (Invitrogen) stock was freshly prepared at 10 µM in 
DMEM. The purified OT-1 CD8+ T Cells were washed with DMEM and labeled with 
2.5 µM CFSE for 10 minutes at 37C in dark. The reaction was stopped quickly 
with DMEM containing 2% FCS, centrifuged, washed and resuspended in 2 ml 
DMEM containing10% FBS buffer. The cells were counted and diluted to 1 X 
106/ml density for plating. 
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BMMCs and T-cell co-cultures  
The stock of SIINFEKL peptide (Sigma) was prepared in 1X PBS at 0.5 
mg/ml concentration and stored at -200C.  BMMCs from WT and D6-/- (2 x 106) 
were incubated with OVA octapeptide SIINFEKL (257-264) (Sigma) for 3 hours in 
4 ml of DMEM containing 10% FBS medium. Following incubation, BMMCs were 
washed three times and resuspended in DMEM containing 10% FBS medium. For 
co-culture experiments, 1 X 106 CD8+ T Cells or CFSE labeled CD8+ T cells were 
mixed with different ratios of BMMCs that were prepared in 3 ml DMEM containing 
10% FBS and cultured in 12 well plates for 48 hrs (activation) or 72 hrs 
(proliferation) respectively. CD8+ T cell activation was measured by surface 
expression of CD69, CD44 and CD25 by Flow cytometry. The CD8+ T cell 
proliferation was determined using CFSE labeled CD8+ T cells by following CFSE 
dilution. 
Flow Cytometry  
Cells were taken into 12 x 75 mm round bottom polypropylene tubes, 
washed with 1X PBS and centrifuged at 450 g for 3 min. The cell pellet was 
resuspended in 50 µl 1XPBS containing 1% BSA and Fc blocked for 20 minutes 
on ice with 1 µg of Rat anti mouse CD16/CD32 (2.4G2) antibody. After Fc block, 
specific fluorescence labeled antibodies were added at a concentration 
recommended by manufacturer or titrated in the laboratory and incubated on ice 
protecting from light. After 40 minute labeling, cells were washed with cold 1XPBS, 
centrifuged at 400 g for 3 minutes and fixed with 1 X PBS containing 2% 
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Paraformaldehyde. The cell viability was measured using 0.5 µl of fixable viability 
Dye eFluor 660 (e-bioscience) in 500ul 1XPBS. 
Intracellular IFN-γ staining  
The cells were stimulated for 5 hours with 1X cell stimulation cocktail 
containing phorbol 12-myristate 13-acetate (PMA) and ionomycin (e-bioscience), 
washed, permeabilized and stained with Rat anti mouse IFN-γ antibody according 
to e-Bioscience instructions using their buffers. 
Purification of immune cells  
T and B cells were isolated by incubating with their specific rat monoclonal 
antibodies for 45 minutes, washing and incubating with magnetic anti rat antibodies 
and purified on MACS MS columns according to manufactures instructions. 
Immunofluorescence  
The distal intestine tissue was filled with OCT compound, Swiss rolled and 
mounted with OCT. The OCT block was rapidly frozen by immersing in cold 2-
Methybutane chilled with dry ice. The OCT frozen tissue was cut into 6-7 µm size 
sections using Leica CM1900 Cryostat, placed onto super frost slides and  fixed in 
cold acetone (-200C) for 10 minutes. After air drying for one hour, serial sections 
were washed with 1X PBS and blocked for 30 minutes with 5% goat serum 
followed by incubation with primary Rat-anti mouse antibodies [CD8 (BD 
Biosciences, MCPT-1 (e-Bioscience)] or isotype antibodies (at 1/50 dilution) for 60 
min at room temperature in humidified chamber. After incubation, the slides were 
washed with 1X TBS and added secondary goat anti-rat IgG AlexaFluor 488  at 
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1/500 dilution and incubated for 30 min. Sections were counterstained with DAPI-
1, mounted using Vectashield mounting medium (Vector labs) and visualized on  
Nikon A1R confocal  Microscope using appropriate filters.  
BMMCs double staining:  BMMCs (1x106) were washed and spread on superfrost 
slides in 70 µl volume using Shandon cytospin centrifuge. Cytospin preparations 
of BMMCs were stained indirectly using Rat anti CD117 and Biotin labeled anti-
FcεR1 antibodies and visualized by Green Alexa-488 labeled anti rat antibody and 
Red Alexa-647 Streptavidin. The immunofluorescence images were captured 
using Nikon A1R confocal microscope using appropriate filters.  
Statistical analysis  
The number of animals (n) were calculated using ‘Two-sample t test’ in 
Web-based power analysis versions that is available at, 
http://www.stat.uiowa.edu/~rlenth/Power/index.html. The ‘n’ was chosen to give an 
approximately 80% chance of detecting the difference with no more than 5% 
chance of error. Standard Mann-Whitney U non-parametric two-tailed and two-
tailed Student’s t-test were used for comparisons between two experimental 
groups, with a p value of <0.05 considered as significant using Graph Pad Prism 
software (***=p<0.001; **=p<0.01, *=P<0.05). The significance of survival of 
animals was calculated using Kaplan-Meier survival curves by the Mantel-
Haenszel/Log-rank test.
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CHAPTER III 
 
MAST CELLS ARE TUMOR PROTECTIVE IN D6-/-APCMIN/+ MICE 
 
INTRODUCTION 
 Increase in mast cell numbers correlated well with good prognosis in human 
colorectal cancer [58, 86], breast cancer [49-51, 87] and prostate cancer [55, 56]. 
In Apc∆468 mice, a different allele of APC gene, intestinal tumors develop very 
rapidly [88]. In this case, mast cells are more abundant in intestinal adenomas than 
in normal intestine [88]. In contrast, when mast cells were depleted genetically by 
crossing ApcMin/+ mice with c-kitW-sh/W-sh (Sash or SA) mice, intestinal adenomas 
increased in number and size indicating a protective role for mast cells in 
tumorigenesis [64]. Studies in our laboratory also suggested that mast cells might 
play a protective role in the tumor onset in D6-/-ApcMin/+ mice compared to ApcMin/+ 
mice.  We observed increased number of mast cells and mast cell chymase activity 
in intestinal tumors of D6-/-ApcMin/+ compared to ApcMin/+ mice. Therefore, we 
hypothesize that depletion of mast cells in D6-/-ApcMin/+ will increase the 
intestinal tumor burden in D6-/-ApcMin/+ mice.  To address the role of mast cells 
in the development of intestinal tumor development in D6-/-ApcMin/+, we have 
selected genetic methods to deplete mast cells.  This approach offers relatively 
more reliable method, despite some potential for pleotropic effects, to resolve the 
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issue, whether increased mast cell numbers in D6-/-ApcMin/+ is the cause or 
consequence of reduced intestinal tumorigenesis in D6-/-ApcMin/+mice. WBB6F1- 
kitW/W-v and C57BL/6-kitW-sh/W-sh are the two commonly used strains with mast cell 
and melanocyte deficiency. The W-sash mutation is an inversion mutation in the 
transcriptional regulatory elements upstream of the Kit transcription start site that 
originally arose spontaneously. The adult c-kitW-sh/W-sh mice lack mast cells in all 
tissues but exhibited normal B cells, T cells but show some myeloid abnormalities, 
in particular increased numbers of neutrophils. The c-kitW-sh/W-sh (SA-/-) mice are 
neither sterile nor anemic and preferred over other mast cell deficient strain 
KitW/KitW-v mice with these phenotypic abnormalities.  
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RESULTS 
Generating D6-/-SA-/-ApcMin/+ mice 
The mast cell deficient SA-/- mice were crossed with D6-/-ApcMin/+ mice to 
generate D6-/-SA-/-ApcMin/+ along with control SA-/-ApcMin/+ mice. The breeding 
scheme is outlined in detail in Fig. 7A. Briefly, D6-/-ApcMin/+ mice were crossed with 
SA-/- mice to generate heterozygous D6+/-SA+/- mice with or without ApcMin/+ allele. 
The heterozygous male mice with ApcMin/+ allele were then crossed with D6+/-SA+/- 
and SA-/- females for several rounds to obtain D6-/-SA-/-ApcMin/+ and SA-/-ApcMin/+ 
male breeders as well as D6-/-SA-/- and SA-/- female breeders. The representative 
images of breeding strains depicted in Fig. 7B.  To reduce the stress during 
pregnancy from disease, only male breeders with ApcMin/+ allele were used. SA-/- 
mice are prone to anxiety [89] and due to higher rate of cannibalism, the colony 
was maintained with several more breeding setups than normal colony.  
Decreased survival and increased tumor burden in D6-/-SA-/-ApcMin/+ mice 
relative to D6-/-ApcMin/+ mice  
The D6-/-SA-/-ApcMin/+ mice were maintained under the same conditions as 
D6-/-ApcMin/+ mice and their survival was monitored. The mice were always 
maintained on breeders chow with autoclaved water in barrier animal facility. The 
survival advantage observed in D6-/-ApcMin/+ mice was lost with the mast cell 
deficiency. The D6-/-SA-/-ApcMin/+ mice lived on average 180 days, close to the 
ApcMin/+ mice average lifespan (Fig. 8A). The hematocrit values of D6-/-SA-/-ApcMin/+ 
mice at 110 day age are significantly lower than ApcMin/+ mice indicating faster 
disease progression in the absence of mast cells (Fig. 8B). The SA-/-ApcMin/+ mice 
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showed even more severe disease with average HCT values around 15 compared 
to D6-/-ApcMin/+ with an average of 42. We then studied the intestinal tumor burden 
in D6-/-SA-/-ApcMin/+ along with the control SA-/-ApcMin/+ mice at 110 days age. As 
described in the methods, small intestine was divided in to three equal parts (distal, 
middle and proximal sections) and counted under stereomicroscope. Tumors were 
graded into four size ranges 0.1 to 1mm, 1-2 mm, 2-3 mm and 3 mm and above 
using reticles attached to microscope eyepiece. The representative images of 
distal intestines in Fig. 9A shows SA-/-ApcMin mice has more tumors than D6-/-SA-
/-ApcMin/+ and D6-/-ApcMin/+. The total number of polyps in the small intestine of D6-
/-SA-/-ApcMin/+ mice increased slightly but not significantly from D6-/-ApcMin/+ mice 
(Fig. 9B). The SA-/-ApcMin/+ mice has significantly higher number of tumors 
compared to D6-/-ApcMin/+ and D6-/-SA-/-ApcMin/+ but did not show any difference in 
tumor numbers in comparison with ApcMin/+. All the polyp numbers are tabulated in 
Table 1. 
 There is no significant difference in tumor numbers in different regions of 
small intestine between D6-/-ApcMin/+ and D6-/-SA-/-ApcMin/+ (Fig.10A). The increase 
in tumor burden in SA-/-ApcMin/+ from D6-/-SA-/-ApcMin/+ is more prominent in distal 
region and slightly less in proximal region and no change in the middle region. It is 
possible that the regional differences exist in the tumor initiation along the length 
of the intestine. The complete mechanisms for this phenomenon are unknown. In 
Fig.10B, total number of polyps were plotted again as a histogram and compared 
with the size distribution of these polyps in the small intestine. Even though no 
difference in total number of number of polyps in D6-/-SA-/-ApcMin from D6-/-ApcMin/+, 
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the tumor sizes increased significantly in 1-2 mm, 2-3 mm and 3 mm and above 
range in both in SA-/-ApcMin/+ and D6-/-SA-/-ApcMin/+. The tumor numbers are 
significantly reduced in the range of 0-0.1 mm in D6-/-SA-/-ApcMin and this  could be 
due to enhanced growth rate of tumors in the absence of mast cells. The 
representative H & E staining (Fig.11) of the small intestinal sections also show 
the presence of large tumors in the distal intestine of D6-/-SA-/-ApcMin and SA-/-
ApcMin/+ compared to mice sufficient with mast cells. 
Increased inflammation in D6-/-SA-/-ApcMin/+ compared to D6-/-SA-/-ApcMin/+ 
tumors  
As indicated in the background section, expression of markers of 
inflammation such as COX2 and TNF-, are reduced in the small intestinal tumors 
from D6-/-ApcMin/+ mice relative to ApcMin/+ mice. To examine the expression of 
inflammatory markers in the tumors in mast cell deficient mice total RNA was 
isolated from distal intestine tumors and control intestines and analyzed for the 
expression of tumor promoting inflammatory markers COX-2 and TNF-α. As 
shown Fig. 12 both COX2 and TNF-α are up-regulated in tumors of D6-/-SA-/-
ApcMin/+ compared to D6-/-ApcMin/+ mcie. 
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Breeding scheme 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Generation of Mast cell deficient mice KitW−sh/W−sh (SA-/-) in D6-/-ApcMin/+ 
background. D6-/-ApcMin/+ was crossed with SA-/- mice to generate heterozygous D6+/-SA+/- 
mice with or without ApcMin/+ allele. The heterozygous male mice with ApcMin/+ allele were 
crossed with D6+/-SA+/- and SA-/- females for several rounds to obtain D6-/-SA-/-ApcMin/+ and 
SA-/-ApcMin/+ male breeders. The representative images of mice (different genotypes) are 
shown. 
Parents  (M X F) Selected Progeny
1.  D6-/-ApcMin/+              X  SA-/-          D6+/-SA+/-ApcMin/+   D6+/-SA+/-
2.  D6+/-SA+/-ApcMin/+  X   SA-/-    D6-/-SA+/-ApcMin/+   D6+/-SA-/-ApcMin/+   
and      D6-/-SA+/- D6+/-SA-/-
 D6+/-SA+/-ApcMin/+ X  D6+/-SA+/-       SA
-/-Min SA-/-
3. D6-/-SA+/-ApcMin/+x  D6-/-SA+/-   D6-/-SA-/-ApcMin/+ D6-/-SA-/-
and      
 D6+/-SA-/-ApcMin/+x  D6+/-SA-/-   
4.  D6-/-SA-/-ApcMin/+  X D6-/-SA-/- D6-/-SA-/-ApcMin/+ D6-/-SA-/-
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Figure 8: (A) Decreased survival of D6-/-SA-/-ApcMin/+ mice relative D6-/-ApcMin/+ mice. 
Kaplan-Meier survival curves. Lack of mast cells in ApcMin/+ back ground (SA-/-ApcMin/+) 
decreased the survival of mice compared to ApcMin/+. The survival advantage observed in 
D6-/-ApcMin/+ mice was lost with mast cell deficiency. The median life span for D6-/-SA-/-
ApcMin/+ mice is 180 days, close to ApcMin/+ mice median life span. (B). Hematocrit 
analysis (Anemic status): The D6-/-SA-/-ApcMin/+ mice displayed lower hematocrits relative 
to D6-/-ApcMin/+ mice at 110 days age indicating rapid disease progression in the absence 
of mast cells. The SA-/-ApcMin showed even more severe disease with average HCT values 
around 15.  Statistical analysis was performed using Mann-Whitney U test. ***=p<0.001; 
**=p<0.01, *=P<0.05.  
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Figure 9: Small Intestinal polyp development in mast cell deficient Min mice   A) 
Representative images of longitudinally opened distal intestine from 110 day old SA-/-
ApcMin, D6-/-SA-/-ApcMin/+ and D6-/-ApcMin/+ mice. B) The total number of polyps in the small 
intestine in ApcMin/+ (n=12), D6-/-ApcMin/+ (n=11, D6-/-SA-/-ApcMin/+ (n=11) and SA-/- ApcMin/+ 
mice. After 1X PBS cleansing, the longitudinally opened small intestine was divided into 
three equal segments, and the total polyps were counted by stereo microscope at 10X 
magnification. 
 
50 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: The frequency and size of polyps in small intestine. (A) The small intestine 
was divided into three parts equally as proximal, middle and distal. The longitudinally 
opened sections were used to count the polyps as described in methods. Lack of D6 in 
SA-/-ApcMn/+ background reduced polyp number in proximal and distal intestine compared 
SA-/-ApcMin/+.  (B). The histogram of total polyp number and size distribution in the small 
intestine. Mast cell deficiency increased tumor size in SA-/- ApcMin/+ and D6-/-SA-/-ApcMin/+ 
mice. 
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Figure 11: Increased tumor size in mast cell deficient ApcMin/+ and D6-/-ApcMin/+mice. 
Distal regions of the small intestines of mice (age of 110 days) of the indicated genotype 
were prepared for histopathological examination as described in the methods.  Cross 
section images stained with Hematoxylin and Eosin (H&E) shows increased size of tumors 
in D6-/-SA-/-ApcMin/+ and D6-/-SA-/-ApcMin/+ compared to ApcMin/+ and D6-/-ApcMin/+  The H & E 
images were captured using an Aperio Image scope at indicated magnification. Scale bar 
indicates 1 mm. 
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Figure 12: Increased inflammatory markers in the distal intestine tumors of D6-/-SA-
/-ApcMin/+ compared to D6-/-ApcMin/+. Relative mRNA fold changes of indicated genes in 
the total RNA isolated from wild-type and D6 (small intestines), ApcMin/+, D6-/-ApcMin/+ and 
D6-/-SA-/-ApcMin/+ (small intestinal tumors) were determined using the SYBR green PCR 
method. The expression of each gene was normalized to β-actin and relative fold change 
was determined with WT as the baseline. Data are representative of tumors/tissues 
isolated from at least 4-5 different mice for each genotype. Statistical analysis was 
performed using Unpaired t test (**=p<0.01, *=p<0.05). 
  
0
2
4
6 **
*
F
o
ld
 C
h
an
g
e
COX2 TNF-α
0
2
4
6
*
ApcMin/+
tumors
D6-/-ApcMin/+
tumors
Wild type (WT) D6
-/-SA-/-ApcMin/+ 
tumors
D6-/-
 
53 
 
 
 
 
Table 1: The total number and size of the small intestinal polyps for the indicated 
genotypes are shown. Each value represent mean ± SEM. The percentage of total 
is shown in parenthesis. 
 
Genotype Total 0-1 mm 1-2 mm 2-3 mm >3 mm 
Apc
Min/+
 
(n= 12 ) 
102 ± 7.3 
(100%) 
25.3 ± 3.3 
(25%) 
67.7 ± 5.9 
(66%) 
7 ± 1.9 
(7%) 
2 ± 0.8 
(1.9%) 
D6
-/-
Apc
Min/+
 
(n= 11) 
45 ± 8.4 
(100%) 
20.2 ± 3.8 
(45%) 
20.9 ± 5.6 
(46%) 
2.5 ± 0.7 
(6%) 
1.1± 0.3 
(2.4%) 
D6
-/-
SA
-/-
Apc
Min/+
 
(n= 11) 
60.1  ± 7.9 
(100%) 
6.1± 1.3 
(10%) 
37.7  ± 6.6
(63%) 
12.5 ± 1.9 
(21%) 
3.8  ± 0.7 
(6%) 
SA
-/-
Apc
Min/+
 
(n= 12) 
91.17 ± 5.7 
(100%) 
9.9 ± 1.3 
(11%) 
53.5 ± 3.9 
(59%) 
20.9 ± 1.8 
(23%) 
6.8 ± 1.1 
(7%) 
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DISCUSSION 
  Our previous work suggested that reduced tumor burden in the D6-/-ApcMin/+ 
mice might be due to increased mast cell infiltration into tumors. The data 
presented in this chapter offers genetic evidence for this concept and suggest that 
mast cell infiltration into intestinal tumors might have a strong beneficial effect in 
intestinal tumor progression.  
Previous studies showed that absence of D6 resulted in increased 
inflammation in a variety of models including chemical-induced cutaneous 
inflammation [23, 27], ovalbumin or Mycobacterium-induced lung inflammation 
[28, 29], lipopolysaccharide (LPS)-induced placental inflammation (abortion 
model) [30] and methylcholanthrene/phorbol ester (TPA)-induced skin cancers 
[31]. In contrast, our results presented earlier (Figures 2-3) suggest that loss of 
D6 is protective from developing intestinal tumors in ApcMin/+ background mice. 
Since inflammation is known to promote intestinal cancer in this model, it raises 
the critical questions about how inflammation is altered in the intestines of D6-/-
ApcMin/+ and which immune cell types are mediating the observed protective 
effects. Our experiments with the mast cell deficient mice provided the evidence 
that mast cells could account, at least in part, for this phenotype. The survival 
advantage of the D6-/-ApcMin/+ mice was almost completely lost in the D6-/-SA-/-
ApcMin/+ and the more severe anemia further supports the idea that absence of 
mast cells hastens the disease process in these mice.  
However, analysis of tumor burden reveals a more complex picture of 
intestinal tumorigenesis in the ApcMin/+ mice in the D6-/- and SA-/- backgrounds. 
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Further analysis of the tumor burden in these mice (Table 1) provided some 
answers to the observed phenotype. There are two components to analyze, tumor 
initiation and tumor progression. The total tumor number is indicative of initiation 
and the tumor size range (size) is indicative of progression/growth of tumors. Lack 
of D6 in ApcMin/+ background decreased SI tumors (around 50%). Absence of mast 
cells in ApcMin/+ mice did not affect tumor numbers (tumor initiation), but 
significantly increased the proportion of (7% vs 23%) larger tumors (2-3 mm 
tumors). Likewise, absence of D6 in SA-/-ApcMin/+ background decreased overall 
number of tumors (102 vs 60) but have significantly increased tumor size (6% vs 
21%). These results suggest that mast cells are critical in controlling the size of 
tumors. We postulate that mast cell dependent mechanisms control the tumor 
progression (size), whereas mast cell independent mechanisms might control 
tumor initiation (numbers) in D6-/-SA-/-ApcMin/+ mice. An important unresolved 
question from these experiments is what cellular and molecular mechanisms 
account for the decreased tumor incidence in the D6-/-ApcMin/+ mice. Other 
unpublished results from our laboratory showed that D6-/-ApcMin/+ mice in the Rag2-
/- background displayed a very similar phenotype reported here for the D6-/-SA-/-
ApcMin/+mice i.e., similar tumor incidence but more rapid progression of tumors. 
This suggests that neither mast cells nor the adaptive immune systems are likely 
to control tumor initiation but only play a role in tumor progression. Oncogenic 
transformation was proposed to initiate an inflammatory response termed the 
“intrinsic pathway” that could lead to inflammation that might help eliminate the 
transformed cells [2]. Only when the innate response fails to eliminate the 
 
56 
 
transformed cells then tumor will form. It is possible that absence of D6 could lead 
to a heightened innate response (increased mast cells and possible increase 
chemokines due to lack of decoy function of D6) there by effective elimination of 
transformed cells leading to reduced tumor incidence in the D6-/-ApcMin/+ mice. 
Additional experiments targeting innate immune system are required to verify this 
hypothesis [40]. Inflammation is a well-known promoter of tumor development. In 
the ApcMin/+ model of spontaneous intestinal carcinogenesis, loss of MyD88, a key 
mediator of toll-like receptor (TLR)-pathway induced inflammation, is highly 
protective [90]. A number of other studies also demonstrated a clear association 
of increased inflammation to the rapid development of intestinal tumors [90-93]. 
Our studies showing that inflammatory markers, such as TNF- and COX2 are 
decreased in the small intestinal tumors of D6-/-ApcMin/+ compared to ApcMin/+ mice 
and increased in D6-/-SA-/-ApcMin/+mice are also consistent with inflammation 
promotion of adenomas. The mechanisms behind this increase in inflammation in 
the D6-/-SA-/-ApcMin/+mice are unclear at this time. 
 Two other important questions on the role of mast cells in D6-/- ApcMin/+mice 
are 1) what are the mechanisms for their enhanced accumulation in the SI tumors 
and 2) what are the mechanisms by which they slow tumor growth. These 
questions will be addressed in chapter IV and V, respectively. 
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CHAPTER IV 
MECHANISMS OF MAST CELL HOMING IN D6-/-APCMIN/+ MICE 
 
INTRODUCTION 
  Characterization of D6-/-SA-/-ApcMin/+ mice showed that mast cells play a 
protective role in intestinal tumorigenesis. Recruitment of mast cells in to tumors is 
known from Ehlrich’s days (reviewed by Beaven M [94]) and their role in various 
human and murine cancers is discussed extensively in Chapter I. The c-Kit-SCF 
axis plays crucial role not only in mast cell development, migration to gut mucosa, 
proliferation and activation but also involved in their recruitment to tumors [67, 95]. 
The chemokines, CCL2 (MCP-1) and CCL5 (RANTES) are also involved in mast 
cells recruitment to pancreatic islet tumors [48]. Murine mast cells express several 
chemokine receptors and their expression levels are modified under inflammatory 
conditions [66]. All tissue mast cells are derived from heamatopoietic stem cells 
that differentiate into circulating mast cell progenitors (MCPs). Development of 
methods to purify HSCs and selectively amplify and culture mast cell progenitors 
that differentiate into mature mast cells has been valuable to study mast cell 
functions in vitro [96]. The in vitro cultured mast cells are also routinely used in 
adoptive transfer experiments for in vivo functional analysis. We hypothesize that 
altered expression of chemokine and chemokine receptors in mast cells play 
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critical role in enhancement of their tumor infiltration. To determine which of 
the chemokines and chemokine receptors involved in the enhanced recruitment of 
mast cells in D6-/-ApcMin/+ tumors and to perform adoptive transfer experiments, we 
generated and cultured bone marrow derived mast cells (BMMCs) from C57BL/6 
and D6-/- mice.  
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RESULTS 
Phenotypic characterization of bone marrow derived mast cells (BMMCs) 
BMMCs were generated and cultured as described in the methods with the 
addition of stem cell factor (SCF) and IL-3. The purity of these cultures were tested 
by staining with mast cell specific markers CD117 and FcϵR1 and analyzed by flow 
cytometry. They become homogeneous at around four weeks of culture and 
confirmed by surface staining for either CD117 or FcϵR1 or both (Fig. 13A). The 
BMMCs were also identified by double Immunofluorescence staining and confocal 
microscopy analysis for CD117 (green) and FcεR1 (Red) expression (Fig.13B). 
Over 95% of the cultured cells stained for both CD117 and FcεR1. BMMCs grow 
slowly in suspension and requires sub culturing every five days. For most 
experiments, healthy cells cultured for 6 to12 weeks were used.  
Microarray analysis of BMMCs from wild type (WT) and D6-/- mice 
To identify the potential mechanisms involved in the enhanced migration of 
D6-/- mast cells, we examined the global changes in gene expression patterns 
between the WT and D6-/- mast cells by microarrays. We were particularly 
interested in differences in the chemokine and chemokine receptor gene 
expression patterns in D6-/- mast cells in comparison with WT mast cells. In 
addition, we also wanted to explore differences during the in vitro development of 
mast cell differentiation. Therefore, total RNA was isolated from 2 week and 10 
week old mast cells and analyzed on Affymetrix mouse microarray chips as 
described in the methods. To obtain pure mast cells from two week old culture, 
BMMCs were purified on MACS column using CD117 antibody. According to heat 
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map analysis (Fig.14) several genes are differentially expressed between the wild 
type and D6-/-mast cells either at 2 weeks of age or at 10 weeks as well as during 
the mast cell development from 2 weeks to 10 weeks. Of interest to the current 
study, chemokine receptors CCR2 and CCR5 genes are highly up regulated in D6-
/- mast cells cultured for two weeks (Fig.15A) or 10 weeks (Fig.15B) compared to 
WT mast cells.  
Increased expression of CCR2 and CCR5 in D6-/- BMMCs  
Microarray data was confirmed by analyzing CCR2 and CCR5 gene 
expression using specific primers in RT PCR analysis. Amplification plots (Fig. 
16A) showed that the CCR2 and CCR5 mRNAs (Fig. 16B) in D6-/- amplified much 
earlier than WT, whereas the house keeping gene β-actin expression level is 
similar in WT and D6-/- BMMCs. The CCR2 and CCR5 mRNA levels were 
significantly increased in D6-/- BMMCs compared to WT (Fig.16A and 16B right 
panels). We also examined the expression profiles of several CC, CXC chemokine 
receptors and leukotriene receptors BLT1, BLT2 (Fig. 17). There were no 
significant differences in the expression levels of any of these receptors other than 
CCR2 and CCR5 between the WT and D6-/- mast cells. Since we observed 
substantial increase in CCR2 mRNA expression, we stained with CCR2 antibody 
to determine whether the increase in the mRNA expression correlated with 
increase in the surface protein expression. Flow cytometry analysis (Fig.18) shows 
that CCR2 expression is much higher on D6-/- mast cells whereas CCR2 staining 
on the WT BMMCs is comparable to isotype control antibody. 
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Increased migration of D6-/- BMMCs towards CCL2 and CCL5 
 Next, we asked the question whether these highly expressed CCR2 and 
CCR5 receptors are functional on D6-/- mast cells. WT and D6-/- mast cells were 
used in a standard Transwell chamber assay of chemotaxis with increasing 
concentrations of ligand. The cells migrated into the bottom chamber were counted 
by flow cytometry. The WT and D6-/- mast cells both migrated well towards SCF 
with peak response at 1 nM concentration (Fig. 19 left panel). When increasing 
concentrations of CCL2 or CCL5 were tested, ligands for CCR2 and CCR5 
respectively, only D6-/- mast cells migrated efficiently showing the typical bell shape 
curve, whereas WT mast cells did not show any chemotactic response (Fig.19 
middle, right panels). 
Functional CCR2 and CCR5 receptors on D6-/- BMMCs  
The functionality of CCR2 and CCR5 receptors on D6-/- mast cells was 
further tested using their corresponding ligands, CCL2 and CCL5 (which are also 
D6 receptor ligands) in intracellular calcium flux assay.  D6-/- mast cells are capable 
of releasing calcium in a dose dependent response to CCL2 (Fig. 20A) or CCL5 
(Fig. 20B). WT BMMCs did not respond to either CCL2 or CCL5 even at the 
highest concentration (60 nM) tested. The failure of WT mast cells to signal through 
D6 ligands prompted us to verify that they are not defective in other aspects. Thus, 
WT mast cells were incubated with 100 ng/ml anti DNP-IgE antibody overnight and 
their responsiveness to 60 nM CCL2 and DNP in intracellular calcium flux assay 
was tested. As expected D6-/- mast cells were responsive to both CCL2 and DNP 
signaling (Fig. 21A). The WT mast cells did not respond to CCL2 but responded 
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well to DNP assuring there is no inherent defect with the WT BMMC cultures in 
releasing intracellular calcium upon activation (Fig. 21B).  
Increased CCR2 and CCR5 expression in D6-/- mice is limited to mast cells 
We next asked whether this high expression of CCR2 and CCR5 in D6-/- 
mast cells is a common phenomenon and other leukocytes also expressed such 
high levels of these receptors? The T-cells and B-cells were isolated from spleen 
and mesenteric lymph nodes as described in methods. The total RNA was isolated 
from purified T and B cells and analyzed for CCR2 and CCR5 expression by real 
time PCR (Fig. 22).  As seen in the amplification plots (Fig. 22A and 22B left 
panels) or relative fold changes using the WT as a baseline (Fig. 22A and 22B 
right panels) there is no significant difference between D6-/-and  WT in the CCR2 
and CCR5 expression. There appears to be slight increase in CCR5 expression in 
D6-/- B cells compared to WT B cells. The fold changes in these primary T and B 
cells when compared to fold changes in mast cells are not significant.  
 We also tested other antigen presenting cells for CCR2 and CCR5 
expression in RTPCR. Bone marrow derived macrophages (BMDMs) and dendritic 
cells (DCs) were isolated from WT and D6-/-mice according to the protocols 
described in methods. As seen in the amplification plots (Fig. 23A and 23B left 
panel) or relative fold change using WT as a base (Fig. 23A and 23B right panel), 
we did not observe  any significant difference between D6-/- and  WT in expression 
levels of CCR2 and CCR5  in BMDMs. There appears to be slight increase in 
CCR2 and CCR5 expression in D6-/- BMDCs from WT BMDCs. 
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Developmental changes in CCR2 and CCR5 expression in D6-/- BMMCs 
 It is known that the expression of CCR2 and BLT1 changes during 
maturation of BMMCs [97]. Both these receptors are expressed at high levels in 
mast cell progenitors but mature mast cells appear to lose the expression. To 
examine if the D6-/- mast cells follow similar pattern of changes, we tested the 
mRNA levels of CCR2 and CCR5 at various time points during the development 
of mast cells. As shown in Fig. 24, the relative levels of CCR2 and CCR5 
decreased dramatically during the development of WT mast cells but remained 
unchanged and somewhat elevated during the development of D6-/- mast cells. 
Adoptive transfer of D6-/- mast cells into D6-/-SA-/-ApcMin/+ mice 
 To test the efficacy of cultured mast cells to complement the in vivo 
deficiency of mast cells in D6-/-SA-/-ApcMin/+ mice, we performed several adoptive 
transfer experiments. Result from a typical adoptive transfer experiment is shown 
in Fig.25. In this experiment, four to six weeks cultured D6-/- mast cells (5X106 
cells/mouse) were transferred via  i.p. injection into four week old D6-/-SA-/-ApcMin/+ 
mice and  analyzed for tumor burden at twelve weeks of post transfer. We did not 
see a significant change in either the tumor numbers (Fig. 25A) or their distribution 
across the small intestine (Fig. 25B). We also did not observe a significant change 
in the size distribution of tumors (Fig. 25C). We attempted to verify the homing of 
the transferred mast cells by analyzing the SI tumors for MCPT-1. Consistent with 
the lack of phenotypic reversion we also did not see detectable mast cell infiltration 
into the tumors from D6-/-SA-/-ApcMin/+ receiving adoptively transferred D6-/- mast 
cells. 
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Figure 13:  Characterization of bone marrow derived mast cells (BMMCs). BMMCs 
were cultured as described in methods. (A) Flow Cytometry Analysis of BMMCs cultured 
for four weeks for cell-surface expression of mast cell specific markers CD117 (C-Kit) and 
FcεR1. BMMCs were incubated with either FITC- CD117 (1 μg) or PE-FcεR1 (2 μg) 
antibody or combined (Pink lane – 1 μg of CD117 + 2 μg of FcεR1; Cyan lane – 1 μg of 
CD117 + 4 μg of FcεR1)  as indicated. Isotype control antibody as reference for no 
staining. (B). Double Immunofluorescence staining and confocal microscopy analysis of 
BMMCs for CD117 and FcεR1 expression. Cytospin preparations of BMMCS were stained 
indirectly using Rat anti CD117 and Biotin labeled anti FcεR1 antibodies and visualized 
by Green Alexa-488 labeled anti rat antibody and Red Alexa-647 Streptavidin. Blue, 
DAP1; Green, CD117; Red, FcεR1. The scale bar indicates 10 µm. 
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Figure 14: Microarray heat map analysis of BMMCs cultured from Wild type (WT) 
and D6-/- mice. RNA was isolated from three independent WT and D6-/- BMMC cultures 
collected at 2 weeks and 10 weeks of age and microarrays performed using Affymetrix 
GeneChip® Mouse Gene 1.0 ST Array. The genes differentially expressed between wild 
type and D6-/- and also the changes in the mast cell development from 2week to 10 weeks.  
Red shows highest expression and green shows lowest expression. 
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Figure 15: Expression pattern of chemokines and chemokine receptors in BMMCs. 
Total RNA from BMMCs cultured for two weeks (enriched for CD117 positive cells) (A) 
and ten weeks (B) was analyzed by microarrays as described in the methods. The fold 
changes of expression of the indicated genes were calculated by comparing D6-/- vs WT 
using wild type expression as base line.  Expression of those genes changed at least 2 
fold with p value of 0.05 was plotted. Chemokine receptors CCR2 and CCR5 were up 
regulated most both in 2 and 10 weeks cultured D6-/- BMMC compared to WT BMMC. 
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Figure 16:  Increased expression of CCR2 and CCR5 mRNA levels in D6-/- BMMCs. 
The mRNA levels of CCR2 (A) and CCR5 (B) in BMMCs (WT and D6-/-) were measured 
using real time PCR using SyBR green as described in methods.  The left panels represent 
the amplification plots of -actin, CCR2 (A) and CCR5 (B). Amplification plots showing the 
early amplification of CCR2 and CCR5 in D6-/- BMMCs compared to WT BMMCs. The β-
actin expression level is similar in WT and D6-/- BMMCs. A and B (Right panels): The 
fold change was calculated using WT as base line and results indicate significant increase 
of CCR2 and CCR5 in D6-/- BMMCs.  
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Figure 17:  Expression of chemokine receptors in BMMCs. The mRNA levels of the 
indicated chemokine receptors were measured in total RNA isolated from ten week old 
cultures of BMMCs from the WT and D6-/- mice using SyBR RT PCR protocols. The level 
of expression of each gene was normalized to the WT as baseline. Levels of the 
chemokine receptors tested here are not significantly different from each other. 
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Figure 18:  Increased expression of CCR2 protein in D6-/- BMMCs. The cell surface 
expression of CCR2 was measured using Flow cytometer Analysis on WT and D6-/- 
BMMCs. The cell-surface CCR2 expression is significantly higher on D6-/- BMMCs (Blue 
line), whereas CCR2 staining on the WT BMMCs is comparable to isotype control 
antibody.   
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Figure 19:  Increased migration of D6-/- BMMCs towards CCL2 and CCL5. Differential 
migration of D6-/- BMMCs to CCR2 and CCR5 ligands in chemotaxis assays. Standard 
Boyden chamber chemotaxis assays were performed with WT and D6-/-BMMCs for 3 
hours with different concentrations of indicated ligands as described in methods. Cells 
migrated into bottom chamber were counted by flow cytometry.  Both the WT and D6-/- 
BMMCs migrated at similar levels to SCF (A). When CCL5 (B) and CCL2 (C) were tested, 
only D6-/- BMMCS showed significant chemotaxis. WT BMMCs failed to migrate towards 
CCL2 and CCL5 (B and C). 
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Figure 20: Functional CCR2 and CCR5 receptors on D6-/- BMMCs. The functional 
response of CCR2 and CCR5 was measured using their corresponding ligands, CCL2 
and CCL5 (which are also D6 receptor ligands) using intracellular calcium release flux 
assay as described in Methods. Agonist mediated intracellular calcium release was 
measured as transient  increase in fluorescence of Indo-1 loaded BMMCs. D6-/- mast cells 
exhibited dose response  to CCL2 (A)  and CCL5 (B). WT BMMC did not respond to both 
CCL2 and CCL5 even at high concentration (60 nM) tested. The data presented is one 
representative of the three independent experiments performed. 
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Figure 21: Functional BMMCs. Dinitrophenyl (DNP) induced calcium release. WT 
and D6-/- BMMCs were sensitized overnight with Anti DNP IgE antibody (100 ng/ml) and 
analyzed for DNP induced calcium release in intracellular calcium flux assay. D6-/- BMMCs 
are capable of releasing calcium upon induction with CCL2 and DNP, whereas WT 
BMMCs failed to respond to CCL2 but released similar levels of calcium upon induction 
with DNP.  
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Figure 22:  Expression of CCR2 and CCR5 in T and B cells. The mRNA levels of CCR2 
and CCR5 in T cells (A) and B cells (B) were measured using SyBR green RT PCR 
protocols. The left panels represent the amplification plots of -actin (dotted lines), CCR2 
and CCR5 (solid lines). (B). The fold change in the expression of CCR2 and CCR5 was 
calculated using WT as base line. 
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Figure 23:  Expression of CCR2 and CCR5 in bone marrow derived dendritic cells 
(BMDCs) and bone marrow derived macrophages (BMDMs). The mRNA levels of 
CCR2 and CCR5 in BMDCs (A) and BMDMs (B) were measured using SyBR RT PCR 
protocols. The left panels represent the amplification plots of -actin (dotted lines), CCR2 
and CCR5 (solid lines). Amplification plots showing the similar amplification of CCR2 and 
CCR5 in both D6-/- and WT BMDCs (A) and BMDMs (B). The fold change was calculated 
using WT as base line. 
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Figure 24:  Expression of mRNA levels of CCR2 and CCR5 in BMMCs isolated from 
WT and D6-/- during maturation. RNA from BMMCs at different time intervals (2, 4, 6 
weeks) was isolated and the mRNA levels of CCR2 (left panel) and CCR5 (right panel) 
were measured using real time PCR using SyBR green as described in methods.  Two 
weeks BMMCs were purified on MACS column using CD117 antibody. The fold change 
was calculated using 2 Weeks sample as base line and results indicate down regulation 
of CCR2 and CCR5 in WT BMMCs and unchanged expression in D6-/- BMMCs.  
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Figure 25: Adoptive transfer of BMMCs into D6-/-SA-/-ApcMin/+ mice. BMMCs (5 x 106) 
were given via i.p into 4 week old D6-/-SA-/-ApcMin/+ (n=11) and polyps were analyzed at 
110 days age old.  A. The total number of polyps in the small intestine B. Frequency of 
small intestinal polyps. C. Size distribution of small intestinal tumors. 
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DISCUSSION 
   Since D6 is a well–established scavenger of inflammatory chemokines, we 
anticipated that the absence of D6 might lead to accumulation of some of these 
chemokines leading to selective recruitment of mast cells. While this indeed could 
be one of the mechanisms, the results presented in this chapter uncover an 
unexpected finding and a potential novel mechanism for enhanced migration of 
mast cells into D6-/-ApcMin/+ tumors.  
 Phenotypic and functional characterization of bone marrow derived mast 
cells revealed D6-/- mast cells express functional CCR2 and CCR5 receptors.  This 
finding is exciting because it provides a likely explanation for why more mast cells 
are recruited to D6-/-ApcMin/+ tumors. Both CCR2 and CCR5 along with other 
chemokine receptors like CXCR2 and BLT1 have been implicated in mast cell 
homing to tissues [39]. However, mechanisms of tumor specific recruitment of 
mast cells are still unclear. The question why CCR2 and CCR5 receptors are up 
regulated on D6-/- mast cells is also puzzling. This is unlikely to be a cell culture 
artifact because it is not happening with the WT mast cells. However, further 
experiments using LY5.1 and LY 5.2 alleles as source of WT and D6-/- bone 
marrow to co culture mast cells and distinguish their CCR2 expression levels by 
flow cytometry will reveal any cell autonomous mechanism for increased 
expression of these receptors.  
 There are several potential explanations for why CCR2 and CCR5 are over 
expressed in D6-/- mast cells. Absence of D6 might lead to alterations in bone 
marrow micro environment causing changes in the transcriptional programs in 
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mast cell progenitors that persist in mature mast cells. A second possibility is that 
absence of D6 causes changes in post transcriptional processing specifically in 
mast cells. In this regard, it is known that  the  CCR2 mRNA down regulation has 
been demonstrated during development of  B cells  [98], DCs [99] and monocytes 
[100]. We also detected CCR2 and CCR5 mRNA expression in two week CD117 
purified mast cell cultures and observed dramatic down regulation in 4 and 6 week 
cultures of WT mast cells (Fig 24). Collington et al [101] have reported earlier the 
down regulation of CCR2 mRNA in BALB/c derived BMMCs during 2 week to 6 
week development of the cultures. This appears to be a mechanism to confine 
them into tissues preventing them from emigrating. In contrast, the expression of 
these transcripts persisted in D6-/- mast cells suggesting that post transcriptional 
processing might be altered in the D6-/- mast cells. It would be interesting to study 
the mechanisms involved in the stability of CCR2 mRNA in D6-/- mice. 
 While dramatic up regulation of CCR2 and CCR5 is observed in cultured 
mast cells, their role in enhanced migration into D6-/-ApcMin/+ tumors remains to be 
established. Peritoneal mast cells may be isolated from D6-/- and WT mice and 
stained for CCR2 mRNA and protein expression. Peritoneal mast cells are 
connective tissue type and the relevant mucosal mast cells can only be isolated 
from gut under inflammatory conditions. Attempts were made to isolate mast cells 
from D6-/-ApcMin/+ tumors and mesenteric lymph nodes and stain for CCR2 without 
much success. The percentage of mast cells very low and the CCR2 may be not 
expressing by all the cells. However, these experiments might be repeated by 
pooling tissue or cells from mesenteric lymph nodes of several mice.  
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 It is difficult to show CCR2-CCL2 axis involvement of mast cell migration to 
intestinal tumors by immune histochemical methods. This is because it was 
demonstrated in C57BL/6 strain that CCL2 and CCR2 staining is strong in small 
intestine [102]  and several stromal and tumor cells also express CCL2 and CCR2.  
The role of CCR2-CCL2 axis in mast cell recruitment was thoroughly studied in 
lung mouse model of allergic inflammation using sub lethally irradiated mice and 
bone marrow transfers which gave inconclusive results and indicated the 
complexity in these interactions [101]. To more definitive identification of the role 
of CCL2 in the recruitment of mast cells in to tumor of D6-/-ApcMin/+ mice requires 
the generation and characterization of D6-/-ApcMin/+ in the background of CCL2-/- 
mice (CCL2-/-D6-/-ApcMin/+).  An alternative approach would be the generation of 
CCR2-/-D6-/-ApcMin/+ or CCR5-/-D6-/-ApcMin/+ mice. Unfortunately, making these 
triple knockout mice is not feasible due to their proximal location of D6 and CCR2 
and CCR5 on the same chromosome. 
 While the adoptive transfer experiments did not provide any conclusive 
answers about the role of mast cells, all other data i.e. i) increased presence of 
mast cells in D6-/-ApcMin/+ tumors; ii) increased tumor burden in D6-/-SA-/-ApcMin/+ 
mice; iii) increased chemokine receptor expression on D6-/- mast cells all point 
towards a tumor protective role for mast cells in the intestine. More importantly, 
this data provides an explanation for large number of clinical studies that showed 
enhanced mast cell infiltration is strongly correlated with better prognosis. Unlike 
the well-established methods that exist for adoptive transfer of T- cells, mast cell 
adoptive transfer methods are at a very early stage of development. To this date 
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not a single study on successful adoptive transfer of mast cells into a spontaneous 
mouse tumor model has been published. While we might continue to take an 
approach of transferring mast cells that are easily tractable (GFP or other markers) 
as well as at various stages of development success might not be a definitive 
outcome for this approach. 
 The most important finding reported in this chapter i.e. enhanced 
expression of CCR2 and CCR5 in mast cells could indeed be the basis for many 
earlier phenotypes reported in the D6-/- mice. These include skin inflammation 
studies [23, 103] and the LPS induced fetal loss [30] as well as other phenotypes 
reported in the context of lung inflammation [28]. This leaves us with the remaining 
question on the mechanisms by which mast cells control tumor growth in D6-/-
ApcMin/+ mice.
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CHAPTER V 
MAST CELL MEDIATED T-CELL HOMING AND ACTIVATION REGULATE 
TUMORIGENESIS IN D6-/-APCMIN/+ MICE 
 
INTRODUCTION 
 Studies described in the previous two chapters clearly outlined a protective 
role for mast cells in tumor development in D6-/-ApcMin/+ mice. Mast cells from D6-
/-ApcMin/+ mice could mediate the anti-tumor immunity through a variety of 
mechanisms. First, a direct role for mast cells as anti-tumor effector cells was 
recognized long time back. Peritoneal mast cells isolated and purified from 
chemically induced fibrosarcoma bearing mice or normal mice showed tumor 
killing capability in vitro cytotoxicity assays [71]. Mast cells isolated from normal or 
tumor bearing mice were equally cytotoxic to mouse or rat fibrosarcomas and less 
effective to mouse fibroblasts suggesting this cytotoxicity is tumor specific. 
Second, mast cells are capable of removing aggressive cancer cells by 
phagocytosis [72, 104]. Third, mast cells can phagocytize bacteria and present 
bacterial antigens to CD8+ T-cell hybridomas through MHC1 as efficiently as 
peritoneal macrophages [78]. Fourth, beyond antigen presentation, mast cells are 
capable of producing several soluble mediators as well as cell surface molecules 
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such ICOS-L, PD-L1, PD-L2, OX40L, CD153, Fas and 4-1BB involved in co- 
stimulation of T-cell responses [105]. 
Mast cell produced cytokines IL-1, IL-2, IL-4, IL-10 and IFNγ can modulate 
tumor environment to both positive and negative ways depending on the tumor 
setting [42]. Finally, mast cells are known to produce a diverse array of lipid 
mediators and chemokines that facilitate recruitment of T-cells to the right immune 
compartments such as tissue draining lymph nodes and potentially into tumors.  
 Based on the protective phenotype associated with mass cell infiltration in 
the D6-/-ApcMin/+ mice we hypothesize that mast cell mediated T-cell homing 
and activation regulate tumorigenesis in D6-/-ApcMin/+ mice. 
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RESULTS 
 
Increased mast cell infiltration into D6-/-ApcMin/+ tumors  
Mast cell infiltration into D6-/-ApcMin/+ tumors was previously demonstrated 
by chloroesterase staining on paraffin sections. To co-stain for multiple immune 
cell markers that are not amenable for staining on paraffin sections, we began 
using OCT frozen tissue sections for immunofluorescence studies as an alternate 
approach. Washed distal intestines from the 110 days old mice were frozen in OCT 
and sections were prepared and stained for mast cell protease using rat anti 
mouse MCPT-1 antibody as described in methods. The mast cell infiltration into 
ApcMin/+, D6-/-ApcMin/+ and D6-/-SA-/-ApcMin/+ tumors is shown in Fig.26A. Mast cell 
staining appears diffused as reported earlier in the literature. The tumors from the 
control mast cell deficient D6-/-SA-/-ApcMin/+ mice did not stain for MCPT-1 (Fig. 
26A). Tumor regions were outlined at higher magnification. For each strain, at least 
six different tumors originating from three different mice outlined and the green 
fluorescence intensities with in the tumor outlined regions were measured using 
Nikon Elements software. The relative fluorescence units were plotted (Fig. 26B). 
The D6-/-ApcMin/+ tumors displayed significantly higher MCPT-1 expression 
compared to ApcMin/+. 
Mast cell mediated enhanced infiltration of CD8+ T cells into tumors 
According to our hypothesis mast cells in tumors are capable of recruiting 
CD8+ T cells to tumors and therefore mast cell enriched D6-/-ApcMin/+ tumors will 
have higher number CD8+ T cells. To verify this, distal intestine frozen sections 
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from 110 day old mice were stained with CD8+ antibody specific to alpha subunit. 
The immunofluorescence confocal images of CD8+ T-cell infiltration into ApcMin/+, 
D6-/-ApcMin/+ and D6-/-SA-/-ApcMin/+ tumors are displayed in Fig. 27A. The tumor 
infiltrating CD8+ positive T cells were counted and calculated per 100 mm2 area 
and plotted (Fig. 27B). We have counted at least six tumors in each genotype 
(three different mice per genotype). The infiltrated CD8+ T cell numbers in D6-/-
ApcMin/+mice was significantly higher than ApcMin/+ and D6-/-SA-/-ApcMin/+ mice.  
T-cell independent mast cell recruitment into D6-/-ApcMin/+ tumors 
 It is evident from the above results that increased tumor infiltration of mast 
cells and CD8+ T-cells in D6-/-ApcMin/+. The data suggests that enhanced T-cell 
recruitment in D6-/-ApcMin/+ is mast cell dependent as there was a significant 
reduction in T-cell infiltration in D6-/-SA-/-ApcMin/+ tumors.  How does absence of T-
cells effect mast cell recruitment? This question was addressed using Rag2-/-D6-/-
ApcMin/+ mice. The mRNA was isolated from distal intestine tumors of Rag2-/-D6-/-
ApcMin/+ mice and analyzed for Mcpt-1 and Mcpt-2 expression by RTPCR. Both 
mast cell specific genes are increased in D6-/-ApcMin and Rag-/-D6-/-ApcMin/+ mice 
relative to ApcMin/+ mice (Fig. 28A). The cell lysates prepared from the distal 
intestine tumors of Rag2-/-D6-/-ApcMin/+ mice were analyzed for Mcpt-1 protein 
expression in Western blots (Fig. 28B Left) and quantified (Fig.28B Right). Rag2-
/-D6-/-ApcMin/+ mice tumors showed similar expression of Mcpt-1 as D6-/-ApcMin/+ 
tumors. These results provide direct genetic evidence for T-cell independent mast 
cell recruitment to Min tumors.  
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Uptake and presentation of exogenous peptide antigens by BMMCs  
While mast cells are recognized as effectors in many settings they are also 
known to be capable of taking up exogenous peptides, present them to CD8+ T 
cells through MHC-1 and activate CD8+ T cell proliferation and IFN-γ release [106]. 
To ensure mast cells from D6-/- mice are also as effective as WT mast cells in 
mediating T- cell functions, we performed co-culture experiments using bone 
marrow derived mast cells (BMMCs) and ovalbumin specific CD8+ T cells from OT-
1 TCR transgenic mice. First, we tested the BMMCs for their capacity to take up 
and present exogenous peptide antigens on their surface through MHC-1. Mast 
cells were cultured with or without 1 or 4 µM OVA derived peptide SIINFEKEL for 
3 hours and washed to remove unbound peptide followed by staining with the 
antibody capable of binding to peptide and MHC-1 only in complex and analyzed 
by flow cytometry (Fig. 29). The WT and D6-/- mast cells stained equally well with 
this antibody indicating that D6-/- mast cells can take up the peptide and present 
the same on their surface through MHC-1.  
 We next asked whether BMMCs could present antigens to CD8+ T cells and 
activate them. WT and D6-/- BMMCs were pulsed with 4 μM SIINFEKEL, washed 
and added at different ratios as indicated to 1 x 106 /ml MACS purified CD8+ T cells 
from OT-1 transgenic mice. After 48 hour co-culture, T cell blasts were visible 
under microscope and representative T cell blasts were captured (Fig.30). After 
co-culture, cells were stained for CD8+ T cell activation markers CD69, CD44 and 
CD25 and analyzed by flow cytometry. Both the WT and D6-/- BMMCs pulsed with 
peptide exhibited CD69, CD44 and CD25 maximum upregulation at higher mast 
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cell ratio (1:2) and unpulsed BMMCs at the same concentration did not show this 
response (Fig. 31). These results show D6-/- mast cells can capture and present 
peptide antigens to CD8+ T cells leading to their activation. 
Activation of CD8+ T cells proliferation by BMMCs  
We further investigated the potential of D6-/- mast cells to induce CD8+ T 
cell proliferation by CFSE dilution. BMMCs were pulsed with 4 μM SIINFEKEL, 
washed and added at different ratios as indicated to 1 x 106 /ml MACS purified, 
CFSE labeled OT-1 CD8+ T cells. After 72 hour co-culture, CD8+ T cells were 
analyzed for CFSE dilution by flow cytometry. The mast cell dose dependent 
increase in proliferation of CD8+ T cells was observed where maximum 
proliferation occurred at highest mast cell number to CD8+ T cell ratio for both the 
WT and D6-/- BMMCs (Fig. 32). The inset in the 1:2 ratio is a control showing the 
addition of the same number of mast cells without the peptide on their surface. The 
addition of unpulsed BMMCS even at these high concentrations resulted in only a 
partial single division, whereas cultures with peptide pulsed mast cells showed up 
to five cycles of division. These results show D6-/- mast cells can activate T cell 
proliferation in an antigen specific manner. 
Mast cell mediated cytotoxic potential of CD8+ T cells  
Activated CD8+ T cells reduce the tumor burden by producing the 
intracellular cytokine IFN-γ.   We explored the effector functions of CD8+ T cells 
induced by D6-/- mast cells by staining CD8+ T cells for intracellular IFN-γ 
production after antigen specific activation. BMMCs were pulsed with 4 µM 
SIINFEKEL, washed and added to MACS purified OT-1 CD8+ T cells at 1:2 ratio. 
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After 48 hour co culture and 5 hour stimulation, CD8+ T cells were analyzed for 
intracellular IFN-γ levels by flow cytometry. The CD8+ T cells activated by pulsed 
D6-/- mast cells produced IFN-γ to the same extent as CD8+ T cells activated by 
pulsed WT mast cells (Fig. 33).  Control unpulsed mast cells did not result in any 
significant IFN-γ production from CD8+ T cells.  
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Figure 26: Increased mast cell infiltration into D6-/-ApcMin/+ tumors.  Representative 
images of mast cell infiltration into adenomas are shown. The immunofluorescence 
staining for mast cell specific protease, MCPT-1 was performed. The frozen distal intestine 
(110 days old) sections were stained with Rat anti mouse MCPT-1 antibody and visualized 
by Alexa 488 labeled anti rat antibody. Tumor regions marked with white line, Blue, DAP1; 
Green, MCPT-1. The images were captured using Nikon A1R confocal microscope at 200 
x magnification. The scale bar indicates 100 µm. Quantification of mast cells: From each 
strain six different tumors were outlined and the green fluorescent intensities with in the 
tumors were measured using Nikon Elements software The relative fluorescence units 
were plotted.  The D6-/-ApcMin/+ mice tumors displayed higher MCPT-1 expression 
compared to ApcMin/+ mice. The tumors from the control mast cell deficient D6-/-SA-/-ApcMin/+ 
mice did not stain for MCPT-1. 
(A) 
(B) 
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Figure 27: Mast cell mediated enhanced infiltration of CD8+ T cells into tumors. (A) 
Representative images of immunofluorescence staining of CD8+ T cell infiltration into 
adenomas. The frozen sections of the distal intestines of the indicated mice (110 day old) 
were cut and stained with Rat anti mouse CD8+ antibody and visualized by Alexa 488 
labeled anti rat antibody. Tumor regions marked with white line. Blue, DAP1; Green, CD8.  
The images were captured using Nikon A1R confocal microscope at 200 x magnification. 
The scale bar indicates 100 µm. (B) Quantification of CD8+ T cells: The tumor infiltrating 
CD8+ positive T cells were counted and calculated per 100 mm2 area and plotted. We have 
counted at least 6 tumors in each genotype (3 different mice per genotype). The infiltrated 
CD8+ T cells number in D6-/-ApcMin/+ mice was significantly higher than ApcMin and D6-/-SA-
/- ApcMin/+ mice.  
(A) 
(B) 
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Figure 28: T-cell independent Mast cell recruitment into D6-/-ApcMin/+ tumors. (A) 
mRNA levels of Mcpt1 and Mcpt2 were measured using RT-PCR. There is a significant 
increase in MCPT1 and MCPT2 levels in D6-/-ApcMin/+ and D6-/-Rag2-/-ApcMin/+ compared 
to ApcMin/+ (B) The small intestinal tumors from D6-/-ApcMin/+ and D6-/-Rag2-/-ApcMin/+ were 
dissected and the protein lysates were prepared using RIPA plus buffer. The tumors 
lysates (30 µg) were subject SDS-PAGE and Western blots prepared. The blots were 
probed for MCPT-1. The blot was stripped and probed again for -actin. The quantification 
of blots was performed using the Metamorph software. The protein levels of MCPT1 were 
similar in both D6-/-ApcMin/+ and D6-/-Rag2-/-ApcMin/+.  
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Figure 29:  Uptake and presentation of exogenous peptide antigens by BMMCs. 
Mast cells were cultured with or without 1 or 4 uM peptide SIINFEKEL for 3hours followed 
by staining with the antibody specific to MHC-1 coupled peptide and analyzed by flow 
cytometry. Both the wildtype and D6-/- mastcells stained equally well with this antibody 
indicating D6-/- mast cells can take up the peptide and present the same on their surface 
as well. 
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Figure 30: Induction of CD8+ T cell blasts by peptide pulsed BMMCs. The 
representative images of CD8+ T cell blasts after co-culturing with mast cells for 48 hrs 
were captured using Nikon T300 microscope. BMMCs were pulsed with 4 µM SIINFEKEL, 
washed and added to MACS purified OT-1 CD8+ T cells at 1:2 ratio. After 48 hour co-
culture, clusters of proliferated CD8+ T cell were visible in SIINFEKEL activated wells (right 
panel). The scale bar indicates 100 µm. 
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Figure 31: Antigen specific activation of CD8+ T cells by BMMCs. BMMCs were pulsed 
with 4 µM SIINFEKEL, washed and added to MACS purified OT-1 CD8+ T cells at different 
ratios as indicated. After 48 hour co-culture, the cell-surface expression of CD69, CD44 
and CD25 on CD8+ T cells was analyzed by flow cytometry. Both the WT and D6-/- BMMCs 
mediated CD8+ T cell activation upon SIINFEKEL treatment. 
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Figure 32: Activation of CD8+ T cells proliferation by BMMCs. BMMCs were pulsed 
with 4 µM SIINFEKEL, washed and  added to MACS purified, CFSE-labeled OT-1 CD8+ 
T cells at different ratios as indicated with the CD8+ T-cell numbers fixed at I x 106 per 
assay. After 72 hour co-culture, CD8+ T cells were analyzed for CFSE dilution by flow 
cytometry. The proliferation of CD8+ T cells was maximum at highest mast cell number to 
CD8+ T cell ratio for both the WT and D6-/- BMMCs. The inset in the 1:2 ratio of shows the 
addition of the same number of mast cells without the peptide on their surface.  
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Figure 33: Intracellular staining of CD8+ T cells for IFN-γ.  BMMCS were pulsed with 4 
uM SIINFEKEL,washed, and  added to MACS purified OT-1 CD8+ T cells at 1:2  ratio. 
After 48 hour co culture, cells were stimulated with PMA/ionomycin cocktail for 5 hours 
and analyzed for intracellular IFN-γ levels by flow cytometry. The WT and D6-/- BMMCs 
mediated IFN-γ release from CD8+ T cells upon SIINFEKEL treatment.  
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DISCUSSION 
 The results presented here showed that enhanced mast cell infiltration into 
tumors is intimately linked to facilitated T-cell recruitment into tumors in the D6-/-
ApcMin/+ mice. Moreover, these results place mast cells clearly acting upstream of 
the cytotoxic T-cells. T- Cell recruitment to tumors is dependent on the presence 
of mast cells (D6-/-SA-/-ApcMin/+) whereas the enhanced mast cell recruitment is 
completely independent of the T-cell function (D6-/-Rag2-/-ApcMin/+).  According to 
our hypothesis, activated CD8+ T cells remove tumors by immune surveillance and 
mast cells facilitate this process by directly presenting tumor antigens to CD8+ T 
cells as well as facilitating their recruitment into tumors.  
  Under most inflammatory and infection conditions tissue associated mast 
cell number increases. For example, mast cell numbers in nasal mucosa increases 
during pollen season. The increase in mast cell numbers and induction of mast cell 
proteases 1 (MCPT-1) in intestinal mucosal epithelium during infection by 
helminthes is T-cell mediated [107, 108].  The accumulation of mast cells in a T-
cell independent manner was also noticed in Rag2-/-ApcMin/+mice adenomas [63]. 
Gounaris et al suggested that deficiency of mast cells in Apc∆468 epithelium is unfit 
to propagate and progress in to full tumors [63]. Gournaris et al showed the 
requirement of mast cells in tumorigenesis by using bone marrow transfers of WT, 
KitW-sh/W-sh, Cd34-/-Cd43-/-  into lethally irradiated Apc∆468 mice. They observed only 
25% reduction in polyp number (60 to 45) with KitW-sh/W-sh BM. However, irradiation 
and bone marrow transfers into Apc mice have their limitations and consequences 
in obtaining consist phenotype in spontaneous intestinal cancer models. 
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Therefore, we choose genetic approaches to examine the precise role for mast 
cell requirement in tumorigenesis.  The intestinal adenomas of ApcMin/+ and D6-/-
ApcMin/+ mice are infiltrated with mast cells but the vastly increased mast cell 
infiltration in D6-/-ApcMin/+ mice relative to ApcMin/+ is tumor protective. We believe 
our data presented here outlines a simpler explanation of reduced immune 
surveillance in the absence of T-cells. The phenotype of Rag2-/-D6-/-ApcMin/+ 
generated in our laboratory is similar to the D6-/-SA-/-ApcMin/+ mice with increase in 
overall tumor burden as described in chapter III of this dissertation. It is possible 
that in the absence of T-cells and mast cells might even be tumor promoting but 
certainly do not mediate any direct anti-tumor activities.   
 Several studies pointed out the significance of the tumor infiltrating 
lymphocytes (TIL) within the core of the tumor or at invasive margin as a good 
prognosis factor in colorectal cancer [109, 110]. A recent review highlights most of  
the research in this area [111] not only in colon cancer but also in other cancers  
providing the link between TILS and tumor prognosis. TILS consist of CD4+ helper 
cells or CD8+ cytotoxic cells or both. There are three types of CD4+ T-cell  in tumors 
including CD4+ helper, T-regs and Th17 cells. The balance between CD4+ helper 
cells enhancing CD8+ CTL function or opposing Tregs mediated immune 
suppression will dictate the tumor outcome. A large influx of CD8+ CTLs in the D6-
/-ApcMin/+ mice (Fig. 27) described here clearly points to the overall enhancement 
of immune surveillance function by the absence of D6. While further studies are 
clearly needed to dissect the role and contribution of different CD4+ subsets 
including T-regs, the use of SA-/- and Rag2-/- compound mice outlines the critical 
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importance of mast cell mediated T-cell responses in the initiation of tumor 
protective responses in the Min mice.  
 The data presented here also suggests that D6-/- mast cells can present 
peptide antigens as effectively as WT mast cells. Upon antigen presentation by the 
mast cells, CD8+ cells differentiate into CTLs producing perforin, granzymeB and 
activating the caspases in tumor cells leading to apoptosis. The increased 
apoptosis seen in the D6-/-ApcMin/+ tumors (Fig. 3) suggests that this indeed could 
be the mechanism mediating tumor protection in these mice. Homeostatic 
migration of effector CD8+ T-cells do not need CD4+ help whereas differentiated 
CD8+ T cells need CD4+ help to migrate to viral infection site [112]. CD4+ cells 
secrete IFNγ to help epithelial cells produce CXCL-9 and CXCL-10 for CXCR3 
mediated CD8+ T-cell recruitment. In our system, the mast cell mediated 
production of LTB4 could also be an important mediator of CTL recruitment into 
tumors.  
 Over all the results presented in this thesis outline an important immune 
regulatory function for mast cells, an aspect long suspected from a wide range of 
clinical studies but has not been formally proven. These studies provide a clear 
demonstration of the antitumor potential of mast cells and delineated the 
mechanisms underlying this important function paving the way for development of 
clinical applications based on these principles.
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CONCLUSIONS AND SIGNIFICANCE OF THIS STUDY 
 Cancer is one of the leading causes of deaths worldwide and especially in 
developed countries like the United States. Over the last decade the importance 
of immune system in controlling the development of cancer in both positive and 
negative ways is being appreciated. This research is focused on understanding 
the role of mast cells in controlling intestinal cancer development and the role of 
chemokines in the recruitment of appropriate cells involved in generating effective 
anti-tumor immunity.  A mouse model of intestinal cancer, ApcMin/+ was studied in 
combination with a variety genetic models that lack chemokine decoy receptor D6 
and/or mast cells.  The objective of this study was to reveal the mechanisms 
underlying the observation that absence of D6 led to decreased inflammation and 
reduced tumor development in this model.  
In summary, our results suggest that i) mast cells play a critical role in 
immune surveillance of small intestinal tumors. ii) D6 ligands (CCL2 and CCL5) 
recruit mast cells via enhanced expression of CCR2 and CCR5 in D6-/-ApcMin/+ iii) 
increased accumulation of mast cells facilitate recruitment of CD8+ T-cells in 
intestinal tumors of  D6-/-ApcMin+ iv) D6-/- mast cells can efficiently induce CD8+ T-
cell activation and proliferation v) mast cells are recruited into tumors even in the 
absence of T-cells indicating mast cells act upstream of CD8+ T-cells in mediating 
anti-tumor immunity.
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An important observation from our study is the elevated expression of 
CCR2 and CCR5 in cultured mast cells from the D6-/- mice relative to WT mice. 
While we have not yet formally demonstrated that this increase in CCR2 or CCR5 
is responsible for the enhanced migration of mast cells into D6-/-ApcMin/+ tumors, 
we believe this is the most likely explanation. Further studies showing elevated 
expression of CCR2 on in vivo mast cells either from tumors or draining lymph 
nodes are essential. Demonstration of CCL2 or CCL5 dependent enhanced mast 
cell recruitment in an in vivo model such as skin inflammation or implantable tumor 
models would provide further support to the idea that CCR2 is the cause of 
enhanced mast cell trafficking.  
The most significant contribution of the current study is the demonstration 
that the mast cells directly contribute to enhanced immune surveillance of intestinal 
cancers. Our genetic studies clearly identified the importance of mast cells in 
slowing the tumor progression in the D6-/-ApcMin/+ mice. While the presence of mast 
cells in tumors has been known since the days of Ehrlich, their contribution to the 
tumor promotion or tumor elimination has been a matter of continued investigation 
and debate. Our studies presented here strongly point to a protective role for mast 
cells in this intestinal tumor model. 
Although the chemokine scavenging role of D6 has been known for a 
decade the exact mechanisms through which it regulates inflammation in vivo are 
only beginning to be appreciated. Recent work from theGraham laboratory showed 
that the D6 function at lymphatic surfaces, distinct from the normal role in 
clearance of inflammation. The number of Ly6Chigh monocytes increased in D6-/- 
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mice spleen and blood in CCR2 dependent manner and exhibited enhanced 
immune suppressive activity. Bone marrow transfer experiments showed that the 
absence of D6 expression on lymphatic vessels and not on hematopoietic cells is 
important for the monocyte recruitment [113] . During LPS induced inflammation, 
increased levels of CCL2 accumulation  in D6-/-  mice draining lymph nodes 
recruited high CCR2 expressing CD11b+ Gr1high cells [114]. Blocking CCR2 
inhibited the migration of other cellular flow and restored the migration of antigen 
presenting DCs. This indicate the plausible role of D6 is to prevent accumulation 
of inflammatory chemokines on lymphatic endothelium so that APC can efficiently 
present the antigens. Graham and colleagues suggest that the draining lymph 
node area becomes like a clogged sink in the absence D6 preventing the normal 
flow of leukocytes. However, our results showed a significantly different outcome 
i.e. a more efficient anti-tumor immune response in the absence of D6. While, we 
have not measured the presence and abundance of immature DCs and monocytes 
at the draining lymph nodes, earlier studies from our laboratory noted the presence 
of more mast cells in the draining lymph nodes of ApcMin/+ and D6-/-ApcMin/+ mice. 
Indeed, in the context of generating immunity to the altered self-antigens this 
clogged sink is what might be needed for unconventional antigen presentation by 
APCs such as mast cells. Clearly further work is needed to explore this possibility.  
 Mast cells could orchestrate antitumor immunity at several levels. These 
include direct cytotoxicity and phagocytosis, efficient tumor antigen presentation 
and/or effective CTL recruitment to the tumors. The data from D6-/-Rag2-/-ApcMin/+ 
clearly shows mast cells alone are not sufficient to reduce the tumor burden and 
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CD8+ T-cell mediated immune response is essential. Hence, we do not think direct 
cytotoxicity or phagocytic capabilities of mast cells are the mechanism for the D6-
/-ApcMin/+ phenotype. 
Our co-culture experiments using bone marrow derived mast cells (BMMCs) 
and OT-1 CD8+ T cells showed D6-/-mast cells are capable of efficient antigen 
presentation to mediate CD8+ T cell activation and proliferation. We also showed 
the effector function of CD8+ T cells by measuring their IFN-γ levels upon antigen 
specific activation by D6-/- mast cells. While, we have not directly demonstrated 
tumor antigen uptake and presentation by D6-/- mast cells, there is evidence in 
autoimmunity models for mast cells processing protein antigens and efficiently 
presenting to CD8+ T cells [79]. We believe mast cells in D6-/-ApcMin/+ tumors are 
involved in priming and activating naïve CD8+ T cells by taking up tumor antigens 
and present them in draining lymph node. In addition, recent data suggests that 
naïve T-cells can also be primed directly within the tumors [115]. Mast cells in D6-
/-ApcMin/+ tumors may also be involved in secondary priming and proliferation of 
memory CD8+ T cells for sustained response. We do not know at this time 
involvement of other cell types or whether CD4+ T-cell help is needed. It is also 
unclear the extent or relative contributions of the conventional DCs and/or mast 
cells in initial priming.  
 There are reported instances of tumor reactive CTLs not being efficiently 
recruited to tumors and staying at the periphery in draining lymph nodes failing to 
initiate anti-tumor immune response. We think one of the reasons for effective 
immune surveillance in D6-/-ApcMin/+ tumors is the ability of mast cells to produce 
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several T-cell chemoattractants such as LTB4, CCL5, XCL1 and CXCL10 upon 
activation. It is well known that LTB4 produced by mast cells plays a central role in 
recruiting effector CD8+ T cells.  An important observation in this regard is that 
when BLT1-/- mice were crossed onto the D6-/-ApcMin/+ background, not only the 
survival advantage of the D6-/-ApcMin/+ mice was lost but the BLT1-/-D6-/-ApcMin/+ 
mice displayed highly accelerated disease. Further studies on mast cell and T-cell 
recruitment into these tumors will provide a more direct evidence for the mast cell 
mediated LTB4 dependent CTL recruitment into the D6-/-ApcMin/+ small intestinal 
tumors. A model summarizing our findings on the role of mast cell mediated 
immune surveillance in the D6-/-ApcMin/+ mice is shown in Figure 34.  
 Over all the studies reported in this dissertation highlight the role of mast 
cells in immune surveillance of intestinal cancers. What is the relevance of these 
findings to human cancers? The importance of the immune system in controlling 
tumor growth has been recognized to the extent that the recent update of hall 
marks of cancer by Hanahan and Weinberg now includes “avoiding immune 
destruction”  as an emerging hallmark of cancer [116]. This joins the previously 
established hallmark of tumor-promoting inflammation [116] and thus recognizing 
the pivotal role of immune system both in tumor suppression and tumor promotion.  
The importance of the distinct immune cell types as guides for determining the 
prognosis was elegantly reviewed by Galon and colleagues [117]. They mentioned 
mast cells also part of this immune contexture along with Macrophages, MDSCs, 
and B cells but they analyzed clinical outcome using only T cell populations. It is 
very clear from this analysis that 97% of the published papers showed that large 
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infiltration of high density of cytotoxic and memory T cells CD8+/CD45R0 in the 
center and invasive margin of colorectal tumors is correlated with good prognosis.  
 Many clinical studies outlined in the chapter I, examined the clinical 
outcome of mast cell infiltration into tumors.  While many studies reporting mast 
cell presence correlated with good prognosis there are other studies that highlight 
tumor promoting effects of mast cells. Independent of the mechanism of their 
recruitment, the results presented here clearly outline a protective role for mast 
cells in intestinal cancers especially when correlated with CD8+ T cells.  
 Tumors are normally classified using tumor burden (T), presence cancer 
cells in the lymph node (N) and evidence of metastasis (M) called TNM staging. 
Recently it was suggested by several groups to include immune scoring as a new 
prognostic factor and include immune score as part of new tumor classification 
method [118]. The results presented in this dissertation supports the potential need 
to include the presence of mast cells in immune scoring along with CD8+ T cells as 
a positive prognostic factor in intestinal cancers. Thus, approaches to enhance 
mast cell infiltration into tumors might be a strategy to develop immunotherapy 
protocols for colon cancer. 
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Figure 34: A model for reduced tumorigenesis in the D6-/-ApcMin/+mice.  In ApcMin/+ 
mice loss of heterozygosity initiates intestinal tumors. Absence of D6 in this background 
resulted in increased mast cell infiltration into tumors. This is likely due to the increased 
chemokines in D6-/-ApcMin/+ tumors as well as enhanced CCR2 and CCR5 expression on 
mast cells. Mast cell produced chemokines and LTB4 chemoattract cytotoxic lymphocytes 
into the tumors leading to effective immune surveillance and reduced tumor burden in D6-
/-ApcMin/+ mice. 
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Laboratory Research Analyst III  Dec. 1996-Feb 1999 
Department of Cell Biology, Duke University Medical Center, Durham, NC. 
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 Study of endocytic pathways of G protein-coupled receptors, operation of a 
bioreactor for large-scale Sf9 cell culture and expression of receptors, Cloning 
and expression of GST-fusion proteins.   
 
Laboratory Research Analyst II  Sep. 1994- Nov 1996 
Department of Biochemistry, Duke University Medical Center, Durham, NC. 
      
 Developed a procedure for large-scale expression of protein farnesyl transferase 
in Sf9 cells and scaled up the protein purification for crystallization, laboratory 
management. 
 
 Graduate Student Sep. 1987- Dec. 1992 
 Department of Biological Sciences, Hunter College, CUNY, New York. 
   
 Characterization of the DNA-Protein Interactions in a cAMP Regulated Gene of 
Dictyostelium discoideum, isolated complete cDNA clones for Protein 
Phosphatase 2A. 
 
Senior Laboratory Technician Oct. 1984- July 1987 
Department of Pediatrics and Medicine, The Johns Hopkins School of Medicine, Baltimore, 
MD. 
     
 Purification of mitochondrial creatine kinase from chicken hearts, Purification of 
apolipoprotein-E from VLDL, measuring the effect of hyperoxia on endothelial 
cell proliferation. 
 
Junior Research Fellow   Jan. 1982- Dec. 1983 
Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India. 
      
  Propagation of Eucalyptus and Sandalwood by tissue culture. 
 
TEACHING EXPERIENCE:  
            Fall 1989   Molecular biology laboratory course,   Hunter College,   CUNY. 
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RESEARCH EXPERIENCE 
  
Over the years my research projects involved use of a variety of cell and molecular biology 
techniques as well as protein expression, purification, biochemical characterization 
and crystallization for structural studies. Some specific projects are outlined below. 
 
One project involved cloning and expression of novel chemokine genes to identify their 
biological functions and for making antibodies. 
 
Previously I worked in a Howard Hughes lab focused on elucidating the mechanisms in 
mediating internalization of G-protein coupled receptors. I tested the role of various 
dominant negative endocytic mutants in agonist mediated sequestration of multiple 
receptors using mammalian cell transfections, flow cytometry and confocal 
microscopy (PNAS. USA. 95: 7157-7162 (1998).   
 
During my stay in x-ray crystallography lab, I had an opportunity to work as team in 
collaboration with protein biochemistry group to develop a procedure to produce 
milligram quantities of protein farnesyl transferase. I was responsible for setting up 
and operation of a 16-L bioreactor for Sf9 cell growth and protein production. I have 
purified protein farnesyl transferase by scaling up the DEAE-sephacel, Q-sepharose, 
phenyl sepharose column chromatography procedures leading to crystal structure of 
2.25-angstrom resolution (Science.  275: 1800-1804 (1997). Later I have used this 
experience to setup a 36-L bioreactor to produce G-protein coupled receptors. 
My M.Phil work is on the DNA-Protein interactions in a cAMP Regulated Gene of 
Dictyostelium discoideum. These studies identified two major DNA-protein 
complexes C2 and C3, resulting from proteins binding to the AT rich region (BASAL) 
of a developmentally regulated gene were detected using gel mobility shift assays. 
The BASAL binding factor (BBF1) involved in forming the C3 complex, was further 
purified to near homogeneity. BBF1 was identified as a 60-kDa protein by glycerol 
gradient analysis of the native protein and by SDS gel electrophoresis of the protein 
UV cross-linked to its target DNA. The protein involved in the formation of the C2 
complex was purified and identified as a 34-43 kDa protein (BBF2) by glycerol 
gradient analysis and UV cross-linking. Mutational analysis shows that BBFI binds in 
the 5' half of the BASAL region and BBF2 binds in the 3' half. 
PhD Dissertation Project: Chronic inflammation in known to promote cancer of various 
organs and recent studies also point to a critical role for inflammation in 
immunosurveillance of cancer. Chemokines are key mediators of inflammation and 
therefore are likely to play an important role in promoting chronic inflammation 
and/or tumor-eradicating immunosurveillance mechanisms. D6 is a chemokine 
decoy receptor that scavenges many chemokines to regulate tissue inflammation. 
My project is to identify the immune mechanisms involved in the reduction of tumor 
burden in D6-/-ApcMin/+ mice and initial experiments lead to the hypothesis that mast 
cells play a protective role in intestinal tumorogenesis.  Details of this research are 
the subject matter of the current dissertation.  
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